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Adult mammalian skeletal muscle tissue retains inherent regenerative capability in response to 
injury. This regenerative response is contingent upon an activated progenitor cell population and 
a temporal transition from pro-inflammatory M1 to immunomodulatory and constructive M2 
polarized macrophages at the site of injury. Specifically, pro-inflammatory effector molecules 
secreted by M1 macrophages promote the expansion of skeletal muscle progenitor cells, while 
resolution of the inflammatory response and myogenic differentiation of skeletal muscle 
progenitor cells is dependent upon immunomodulatory effector molecules secreted by M2 
macrophages. 
The decline in the regenerative capacity of skeletal muscle tissue associated with 
advanced age is largely a consequence of progenitor cell dysfunction. Furthermore, advanced age 
is accompanied with immunosenesence of the innate immune system resulting in an impaired 
macrophage polarization potential. 
Biologic scaffold materials composed of mammalian extracellular matrix (ECM) have 
been successfully used in both pre-clinical animal studies and in human clinical applications to 
promote constructive tissue remodeling in a variety of anatomic locations including skeletal 
muscle. The presence of ECM bioscaffolds at sites of skeletal muscle injury has been associated 
with a predominant M2 macrophage phenotype and downstream site-appropriate or constructive, 
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functional tissue remodeling. The mechanisms responsible for this constructive tissue 
remodeling response are only partially understood. 
The present dissertation shows that the age of source animals from which ECM 
bioscaffold materials are harvested represents a determinant factor of the constructive tissue 
remodeling potential induced by these materials. The present work also shows that degradation 
products of mammalian ECM promote the constructive M2 macrophage phenotype in both 
young and age-impaired macrophages. Moreover, effector molecules from macrophages exposed 
to ECM degradation products are chemotactic and myogenic for skeletal muscle progenitor cells. 
The present dissertation describes a new rodent model of volumetric muscle loss (VML) and an 
ECM bioscaffold based approach for tissue replacement associated with modulation of 
macrophage phenotype and the endogenous recruitment of perivascular stem cells. 
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1.0 INTRODUCTION AND SPECIFIC AIMS 
This section will introduce biologic scaffolds composed of extracellular matrix (ECM) and 
discuss current tissue engineering and regenerative medicine therapeutic strategies, including the 
use of surgically placed ECM bioscffolds, for the reconstruction of skeletal muscle tissue. The 
role of the innate immune system and myogenic progenitor cells in the context of skeletal muscle 
regeneration and how the aging process negatively affects this system will also be discussed. 
Finally, the central hypothesis and specific aims of the present dissertation will be introduced. 
1.1. BIOLOGIC SCAFFOLDS COMPOSED OF MAMMALIAN EXTRACELLULAR 
MATRIX 
1.1.1. Native Mammalian Extracellular Matrix 
Mammalian extracellular matrix (ECM) is composed of the secreted products produced by the 
resident cells of each tissue or organ. The composition of the ECM is dependent on factors that 
affect resident cell phenotype such as mechanical forces, biochemical milieu, oxygen tension, and 
patterns of gene expression among others. The ECM, in turn, influences the phenotype, chemotaxis, 
mitogenesis, and differentiation of resident cells, and serves as a medium for crosstalk between cells 
(1). For these reasons, the ECM is considered to be in a state of dynamic reciprocity with the resident 
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cell population and to play an important role in normal tissue and organ morphogenesis and 
homeostasis (1, 2). Mammalian ECM is composed of: collagen, fibronectin, laminin, elastin, 
glycosaminoglycans, growth factors, and cryptic peptides among others (1, 3). Collagen is the most 
abundant molecule within mammalian ECM and comprises nearly 90% of its dry weight (4). In 
addition to maintaining the structure of each tissue; cryptic peptides derived from parent collagen 
molecules are known to possess significant biologic activity (5-11). Other functional molecules 
within ECM include growth factors such as vascular endothelial growth factor (VEGF), fibroblast 
growth factor (FGF), stromal derived growth factor (SDF-1), epidermal growth factor (EGF), 
transforming growth factor beta (TGF-β), keratinocytes growth factor (KGF), hepatocyte growth 
factor (HGF), platelet derived growth factor (PDGF), and bone morphogenetic protein (BMP) among 
others (12-16). 
1.1.2. Extracellular Matrix as a Scaffold Material 
Biologic scaffolds composed of extracellular matrix are derived through the decellularization of 
mammalian tissues. The decellularization process incorporates mechanical, chemical, and 
enzymatic processes designed to efficiently promote the dissociation and removal of pro-
inflammatory immunogenic cellular material while preserving the native constituents and 
ultrastructure of the ECM. Upon their surgical placement at sites of tissue injury, ECM 
bioscaffolds have been shown to promote constructive tissue remodeling. Constructive tissue 
remodeling alters the default scar tissue forming mammalian response to injury and promotes 
site-appropriate tissue formation. 
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1.1.3. Default mammalian injury response vs. constructive tissue remodeling 
The default mammalian response to injury is highly conserved among tissue types and occurs in 
three overlapping yet distinct phases: the inflammatory phase, the proliferative phase, and the 
remodeling phase (17). The inflammatory phase occurs immediately after tissue damage and is 
marked by activation of the coagulation cascade and the subsequent influx of innate 
inflammatory cells that facilitate the removal of cellular debris and infection prevention. 
Specifically, hemostasis is achieved through the deposition of a provisional fibrin matrix which 
acts as a scaffold for infiltrating neutrophils and macrophages (18). The proliferative phase is 
characterized by angiogenesis as well as the migration, proliferation and differentiation of 
different cell types (19, 20). During the remodeling phase macrophages and endothelial cells are 
subject to apoptosis while fibroblasts and myofibroblasts produce and deposit a collagenous 
extracellular matrix. This relatively acellular fibrous matrix is the precursor of scar tissue, which 
typically replaces site appropriate functional tissue within the injury site. 
In contrast, host constructive tissue remodeling is a process by which the default healing 
response to injury is modified from one that results in scar tissue formation to one that results in 
the formation of site appropriate functional tissue. Mechanisms behind an ECM scaffold 
mediated constructive remodeling response to injury are discussed below and include the 
participation of an activated host progenitor cell population and a predominant M2/Th2 restricted 
immune response among others (8, 21, 22).   
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1.1.4. Mechanisms of extracellular matrix bioscaffold mediated constructive tissue 
remodeling 
While the exact mechanisms behind the ability of ECM based bioscaffolds to promote 
constructive tissue remodeling remain only partially understood, there are a number of processes 
which are believed to be key contributors. Among these processes are the ability of the scaffold 
material to degrade rapidly with concomitant release of bioactive matricryptic peptides, the 
ability of the scaffold material to recruit stem / progenitor cells, and the ability of the scaffold 
material to elicit a constructive host response which does not result in a foreign body response or 
immunologic rejection of the implant. Each of these processes is discussed below, and explored 
in further detail in the studies which comprise the present dissertation.  
1.1.4.1. Degradation of Extracellular Matrix Bioscaffolds 
ECM scaffolds degrade rapidly in vivo. Studies have shown that surgically placed ECM scaffolds 
become 60% degraded at 30 days post-implantation and 100% degraded after 90 days (23). 
During this period, the scaffold becomes populated and degraded by host-derived mononuclear 
cells and ultimately results in the formation of site-specific functional host tissue histologically 
indistinguishable from native tissue. The scaffold degradation process is mediated by 
inflammatory cells, such as macrophages, which produce proteolytic enzymes that facillitate the 
degradation of the matrix scaffold material (23-25).  
ECM scaffolds have also been degraded ex vivo by chemical and physical methods (26). 
Recent findings suggest that the degradation products of ECM scaffolds are bioactive (6, 7, 9, 
10). Studies have shown antimicrobial activity associated with the degradation products of ECM 
scaffolds; however, in the absence of degradation, antimicrobial activity was not seen, 
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suggesting that some of the bioactive properties of the ECM are derived from its degradation 
products rather than from whole parent molecules present within the ECM (9, 26). Furthermore, 
a low molecular weight peptide derived from the collagen III parent molecule has been shown to 
possess osteogenic potential (6). Degradation products of ECM scaffolds have also been shown 
to be chemotactic for progenitor and non-progenitor cell populations (5, 7, 8, 10, 27, 28) and to 
influence the host innate immune response (9, 21, 22, 29-31). 
1.1.4.2. Recruitment of Progenitor Cells by Extracellular Matrix Bioscaffolds 
Surgically placed ECM scaffolds and their degradation products have been associated with the 
recruitment of endogenous stem / progenitor cells. This phenomenon, including recruited cell-
types, is discussed in detail under section 1.2 of the present dissertation. In general, biologic 
scaffolds composed of mammalian ECM have been shown to be chemotactic for a diverse array 
of stem / progenitor cells with robust differentiation potentials. For example, primitive Sox2+ 
cells were shown to be present at the site of ECM implantation in an adult mammalian model of 
digit injury (5, 27), while multipotent bone-marrow derived cells were shown to participate in the 
remodeling of ECM scaffold mediated Achilles tendon repair (32). Specifically, in the preclinical 
Achilles tendon injury model, ECM scaffold explants promoted chemotaxis of progenitor cells 
after 3, 7, and 14 days of in vivo remodeling (8). The results of the study showed greater 
migration of progenitor cells towards tendons repaired with ECM scaffolds compared to tendons 
repaired with autologous tissue and uninjured normal contralateral tendon. These results suggest 
that ECM scaffolds are capable of recruiting progenitor cells to the site of implantation to 
participate in constructive tissue remodeling over the long-term. 
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 Perivascular Stem Cells 
ECM scaffold materials have been shown to influence specialized populations of 
progenitor cells including multipotent perivascular stem cells (PVSC). Specifically, degradation 
products from ECM bioscaffolds have been shown to be chemotactic for PVSCs (5, 7, 11, 33). 
PVSC’s are CD146+, NG2+ cells found in all vascularized tissues of adult mammals and reside in 
a niche encircling microvessels and capillaries where they regulate vasoconstriction (33). 
Outside their niche, these cells are multipotent and give rise to cells from the adipogenic, 
osteogenic, and chondrogenic cell lineages. Furthermore PVSC’s (isolated as CD146+, CD56-, 
CD45-, CD34-, CD144-) have been shown to be highly myogenic and when transplanted into 
areas of injured muscle induce a higher regenerative index when compared to other myogenic 
cell-types (33, 34). Endogenous PVSCs have also been shown to give rise to skeletal muscle 
myoblasts and participate in the adult mammalian regenerative response to skeletal muscle injury 
(35, 36). PVSCs, and other myogenic cell populations, are further discussed under section 1.2 of 
the present dissertation. 
1.1.4.3. The Innate Immune Response to Extracellular Matrix Bioscaffolds 
The host innate immune system and specifically macrophages play a pivotal role in the host 
response to biomaterial implantation. In fact, macrophage depletion prevents the degradation of 
ECM biologic scaffolds in vivo (31). Macrophages have been shown to respond to many 
different implanted biomaterials, including those composed of metals (37), ceramics (38), 
polymers (39), and biologic proteins such as collagens and xenogeneic ECM (31, 40). 
Macrophage mediated foreign body giant cell formation and pro-inflammatory cytokine 
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production are frequently associated with the implantation of non-degradable or synthetic 
biomaterials. However, several recent studies suggest that immunomodulatory macrophages can 
facilitate constructive and site-appropriate tissue remodeling in response to ECM bioscaffold 
implantation (31, 41). Specifically, surgically placed ECM bioscaffolds have been associated 
with a constructive macrophage phenotype. Mechanisms behind this association are examined by 
the present dissertation. 
Innate immunology has previously characterized macrophages as mononuclear 
phagocytes responsible for microbicidal activity and antigen presentation, the removal of cellular 
debris following acute tissue injury, and propagation of a type-I pro-inflammatory immune 
response (42-44). Macrophages are now recognized as a heterogeneous cell population capable 
of immunomodulation and tissue repair (24, 45-51). Specifically, following the Th1/Th2 
nomenclature, macrophages have been categorized according to their functional properties as 
either M1 or M2 (47, 48). M1 or “classically activated” macrophages propagate a pro-
inflammatory response while M2 or “alternatively activated” macrophages promote 
immunomodulation and are constructive. These opposing macrophage phenotypes will be 
discussed throughout this dissertation. Most relevant to the present introduction, is the 
phenomenon of surgically placed ECM bioscaffolds to be associated with the constructive M2 
macrophage phenotype. Moreover, the phenotype of responding macrophages has been found to 
be an important determining factor in the success of an implanted biomaterial scaffold and its 
ultimate remodeling outcome (21, 22).  
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1.2. TISSUE ENGINEERING AND REGENERATIVE MEDICINE APPROACHES 
TO ENHANCE THE FUNCTIONAL RESPONSE TO SKELETAL MUSCLE 
INJURY  
The well-recognized ability of skeletal muscle for functional and structural regeneration 
following injury is severely compromised in degenerative diseases, diabetes, advanced age, and 
following volumetric muscle loss (VML). Tissue engineering and regenerative medicine 
strategies to support muscle reconstruction have typically been cell-centric with approaches that 
involve the exogenous delivery of cells with myogenic potential. These strategies have been 
plagued by poor cell viability and engraftment into host tissue among other limitations. 
Alternative approaches have involved the use of biomaterial scaffolds as substrates or delivery 
vehicles for exogenous myogenic progenitor cells. Acellular biomaterial scaffolds composed of 
mammalian extracellular matrix (ECM) have also been used as an inductive niche to promote the 
recruitment and differentiation of endogenous myogenic progenitor cells. An acellular approach, 
which activates or utilizes endogenous cell sources, obviates the need for exogenous cell 
administration and provides an advantage for clinical translation. The present section examines 
the state of tissue engineering and regenerative medicine therapies directed at augmenting the 
skeletal muscle response to injury and presents the pros and cons of each with respect to clinical 
translation. 
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1.2.1. Background 
1.2.1.1. The Skeletal Muscle Response to Injury 
Skeletal muscle has a robust capacity for remodeling, repair, and regeneration following injury 
(52, 53). This inherent regenerative response consists of three phases: the destruction phase, the 
repair phase, and the remodeling phase (54-56). The degeneration phase involves necrosis of 
parenchymal cells, stromal disruption, hematoma formation, and the influx of inflammatory 
cells. (54, 57). The repair phase is characterized by the activation of quiescent myogenic 
progenitor cells that enter the cell cycle, migrate to the site of injury and become proliferative 
(58, 59). These activated progenitor cells then differentiate and fuse to form multinucleated 
myofibers (55, 60). During the final phase of the skeletal muscle response to injury, referred to 
as the remodeling phase, the regenerated myofibers organize, mature and obtain the ability to 
contract. However, this response is often inadequate to replace functional tissue in certain 
conditions such as inheritable muscle degenerative disease, advanced age, or volumetric muscle 
loss (VML). 
The above phases of skeletal muscle regeneration rely heavily on a population of cells, 
defined anatomically, as satellite cells. Satellite cells constitute the putative muscle stem cell 
compartment and when quiescent, are located between the plasma and basal membrane of 
myofibers (61, 62). Satellite cells asymmetrically divide and, in response to injury, give rise to 
skeletal muscle myoblasts (55). Myoblasts then proliferate, differentiate and fuse to form 
multinucleate and functional contractile skeletal muscle myofibers to complete the regenerative 
response (55, 63).  
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1.2.1.2. Myogenic Progenitor Cells 
In addition to satellite cells and myoblasts, progenitor cells with high myogenic potential have 
been identified within adult skeletal muscle. These cell types include CD133+ progenitor cells, 
muscle-derived stem cells (MDSC’s), multipotent perivascular progenitor cells, and muscle 
derived side-population (SP) cells among others. Multipotent cells with myogenic potential have 
also been isolated from tissues other than skeletal muscle such as bone marrow, adipose, and 
umbilical cord.  
The present section of this dissertation will examine tissue engineering and regenerative 
medicine approaches which utilize the above myogenic cell types through exogenous cell-
therapy or endogenous cell-recruitment. The eventual goal of all therapies is the augmentation of 
the inherent regenerative response of diseased or injured skeletal muscle. 
1.2.1.3. Tissue Engineering and Regenerative Medicine 
Despite the well-accepted ability of skeletal muscle to regenerate following injury, the decline in 
the regenerative capacity associated with age, congenital defects such as Duchenne muscular 
dystrophy (DMD), and massive loss of muscle tissue from trauma, tumor ablation, or prolonged 
denervation resulting in VML represent skeletal muscle pathologies for which the inherent repair 
mechanisms are inadequate. In such cases, the current standard of care includes corticosteroid 
therapy for DMD (64-66) and autologous tissue transfer for VML (67-69). These treatment 
options show limited efficacy and are associated with severe pharmacologic side effects and 
donor site morbidity for DMD and VML, respectively.  
Tissue engineering and regenerative medicine approaches aimed at augmenting the 
skeletal muscle injury response have traditionally involved the in vitro propagation and 
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subsequent injection or implantation of myogenic progenitor cells into areas of injured muscle 
(70-73). More recently, myogenic cells or their precursors have been combined with biologic 
scaffolds in attempts to promote the muscle regenerative response. These approaches attempt to 
develop an implantable tissue engineered muscle construct (TEMC) and typically require a 
period of ex-vivo culture necessary for efficient cellular-scaffold integration. Despite recent 
advancements, the in vitro culture and/or ex-vivo engineering followed by subsequent 
implantation of muscle cells and/or tissue has both technical limitations and associated 
translational hurdles. An engineered functional skeletal muscle construct requires integration 
with the host tissue including functional vascularization, and neuromuscular innervation. In 
addition, any cell-based approach subjects the therapy to more rigorous regulatory standards that 
are associated with both cost and time for the manufacturer/provider.  
An alternative approach has been investigated in which decellularized xenogeneic or 
allogeneic mammalian tissues have been used to create inductive bioscaffolds composed of 
extracellular matrix (ECM). Such scaffolds provide no external source of new cells but rather 
recruit endogenous progenitor cells to sites of scaffold placement/muscle injury. The relative 
efficacy of the cell-based vs. acellular approaches has not been compared in head to head studies. 
Therapies which use cell based approaches, TEMC’s, and acellular scaffolds will be discussed 
herein (Figure 1). 
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Figure 1: Tissue Engineering and Regenerative Medicine Approaches Aimed at Augmenting the Skeletal 
Muscle Response To Injury. The cell-therapy approach employs the administration of exogenous myogenic 
progenitor cells into sites of skeletal muscle injury via intramuscular injection. The second approach seeks to 
develop an implantable tissue engineered muscle construct (TEMC) composed of exogenous myogenic cells coupled 
with a biomaterial scaffold. The acellular approach employs the implantation of biologic scaffolds composed of 
decellularized mammalian tissue, which upon their degradation, recruit endogenous myogenic progenitor cells. 
These approaches share the same goal in that they seek to restore site appropriate and functional skeletal muscle 
tissue. 
1.2.2. Cell-Therapy Approach 
1.2.2.1. Overview  
The concept of a purely cell-based approach is designed to increase the local pool of cells with 
myogenic potential; an approach which would logically augment and support the inherent 
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regenerative response of injured skeletal muscle. A variety of stem/progenitor cells are 
candidates for such an approach. 
1.2.2.2. Muscle-Derived Progenitor Cells 
Myoblasts 
Satellite cells reside beneath the basal lamina of normal adult skeletal muscle fibers and 
comprise only 2-7% of muscle associated cells (55, 59). These quiescent muscle progenitor cells 
become activated in response to stress from muscle overstimulation or injury and enter the cell 
cycle. Through asymmetric division, activated satellite cells replenish the quiescent satellite cell 
pool and give rise to committed myogenic precursor cells known as myoblasts (55). Skeletal 
muscle myoblasts proliferate, differentiate, and fuse with other myoblasts or to existing damaged 
myofibers to form new skeletal muscle. Following recoverable injuries such as weight bearing or 
exercise, myoblasts are able to fully repair damaged muscle fibers and eventually restore normal 
structure-function relationships. Pathologic conditions such as DMD or irrecoverable volumetric 
muscle loss (VML) involve types of muscle defects for which endogenous myoblasts are unable 
to fully compensate (74-76).  
It is now well accepted that other muscle-derived stem cells or circulating progenitor 
cells possess myogenic potential and can contribute to new skeletal muscle formation. However, 
the satellite cell derived myoblast represents the primary cell type responsible for inherent 
skeletal muscle repair and regeneration. Transplantation of allogeneic myoblasts into injured 
muscle has been extensively investigated, especially as therapy for DMD. The initial preclinical 
demonstration that myoblast transplantation could restore dystrophin expression in animal 
models occurred as early as 1989 (77). A series of clinical trials resulting in unfavorable 
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outcomes were soon to follow (70, 71, 78-82). Although largely unsuccessful, these early clinical 
trials provided valuable insights surrounding the pathobiology of muscle cell implantation. The 
following fundamental problems with the current myoblast implantation procedures were 
identified: (1) At 3 days post-implantation less than 25% of the donor myoblasts remained viable 
(83, 84); (2) Donor myoblasts were incapable of significant migration from the injection site 
(85); (3) Inadequate immunosuppressive therapy resulted in the rapid rejection of donor cells 
(86); and (4) Cyclosporine mediated immunosuppression induced myoblast apoptosis (87, 88).   
There are now partial solutions for these problems. The transfer of a greater number of 
cells can compensate for the poor post-implantation cell viability (85). A subset of pre-myoblast 
satellite cells has been identified that, when injected into models of DMD, result in an efficient 
and functional engraftment (89, 90). The low migration pattern associated with injected 
myoblasts has been partially addressed by transplant protocols that utilize an increased number 
of adjacent intramuscular injections resulting in more evenly distributed cell delivery (91). 
Moreover, Riederer and colleagues postulated that precocious differentiation of injected 
myoblasts prevented their post-transplantation proliferation and migration (92). Indeed, in pre-
clinical models, when myoblasts were prevented from premature cell-cycle exit by using serum 
prior to and during administration, these cells were able to increase in number and colonize a 
much larger area within the recipient’s muscle (92). As for problems associated with the 
prevention of graft rejection, some studies have shown that FK506 mediated immunosuppression 
results in favorable cell transplant outcomes when tested in mice and non-human primate models 
(93, 94). Although less than ideal, when some of these strategies were concurrently employed in 
a human patient clinical trial, they resulted in a 30% restoration of dystrophin expression. (91, 
95, 96).  
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CD133+ Progenitor Cells 
As mentioned above, attempts to transplant cells into injured muscle via intramuscular injection 
have been hampered by the low migratory potential of the injected cells. An alternative approach 
would be to deliver myogenic progenitor cells via the systemic circulation if a mechanism for 
homing the cells to the site of interest were available. To this end, CD133+ progenitor cells 
represent a promising myogenic cell type. Freshly isolated human CD133+ progenitor cells 
express patterns of adhesion molecules commonly associated with cells capable of extravasation 
through the blood vessel wall (76). When enriched CD133+ progenitor cells were injected into 
the systemic circulation of dystrophic mice, the CD133+ cells contributed to muscle repair, 
increased dystrophin expression, and were able to replenish the endogenous satellite cell pool 
(97). In a head to head comparison, muscle derived CD133+ cells injected into injured mouse 
muscle showed a greater replenishment of the satellite cell pool and higher regenerative capacity 
when compared to myoblasts injected in a similar fashion (98). To evaluate safety, Torrente and 
colleagues designed a DMD patient phase I clinical trial in which transplantation of autologous, 
and thus still dystrophic, muscle derived CD133+ cells was conducted.  Results of this trial 
showed no adverse events (99). Future studies will attempt delivery of healthy CD133+ cells 
within the clinical setting.  
Muscle-Derived Stem Cells 
Early myogenic progenitor cells distinct from satellite cells can be separated from other muscle 
cell types based on their adherence to collagen coated flasks in vitro (100). Specifically, early 
adhering cells express satellite cell markers, while late adhering cells express stem cell markers. 
These cells, isolated from muscle digests and capable of long-term proliferation and myogenic 
potential, have been distinctly identified as muscle derived stem cells (MDSC’s) (101). The 
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transplantation of enriched MDSC’s into injured mouse skeletal muscle results in a more 
favorable outcome than the transplantation of skeletal muscle myoblasts (101). Genetically 
engineered MDSC’s transduced with vectors overexpressing different growth factors prior to 
transplantation into dystrophic mouse models, have been associated with higher engraftment and 
better outcomes when compared to native MDSC’s (102). One mechanism behind the improved 
transplantation outcomes of MDSC’s over myoblasts, may be the increased antioxidant levels in 
MDSC’s which allow them to survive oxidative stress associated with the harsh injury and 
transplantation microenvironment (103, 104).  
 
 
Multipotent Perivascular Progenitor Cells 
Perivascular cells encircle the endothelial cells that comprise capillaries and microvessels in all 
vascularized tissues (105). Perivascular cells have been traditionally associated with the control 
and constriction of microvasculature networks (105).  In addition however, perivascular cells or 
subsets of perivascular cells are now accepted to be multipotent (33). It is plausible that 
multipotential perivascular progenitor cells represent a ubiquitous cell-type present throughout 
the microvasculature and represent a reserve cell population capable of responding to injury in 
all tissues. These perivascular stem cells are distinct from other endothelial, hematopoietic, and 
myogenic cells and can be isolated and enriched from human skeletal muscle according to their 
unique surface marker phenotype (33). Perivascular progenitor cells have been shown to 
contribute to developing myofibers in postnatal skeletal muscle development and during the 
inherent response to injury (35). Multipotent perivascular cells are myogenic in vitro, and when 
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injected into cardiotoxin injured mouse skeletal muscle, were able to induce a higher 
regenerative index when compared to enriched and injected myoblasts (33).  
Muscle Side Population Cells 
Muscle side population (SP) cells have been purified from mouse and human skeletal 
muscle using a similar approach originally optimized for the isolation of bone marrow SP cells 
(106). Muscle derived SP cells represent a heterogeneous population of cells distinct from bone 
marrow cells and other muscle derived progenitor cells (107). SP cells have been shown to give 
rise to satellite cells and myoblasts in vivo when injected into models of skeletal muscle injury 
(108, 109). Studies have shown that the systemic delivery of SP cells can result in engraftment 
within dystrophic mouse muscle (107).   
Mesenchymal Stem Cells 
Stem and progenitor cells from outside the skeletal muscle tissue compartment have been 
examined as potential sources of myogenic cells for skeletal muscle tissue engineering. Most of 
these cell populations can be generically categorized as mesenchymal stem cells (MSC’s). Tissue 
sources of MSC’s include bone marrow (110), adipose (111), hair follicles (112), placenta (113), 
umbilical cord (114), and others. MSC’s give rise to tissues of mesodermal origin such as 
adipogenic, osteogenic, chondrogenic, and myogenic differentiation (115). Furthermore, MSC’s 
are pluripotent and have been shown to differentiate into tissues of ectodermal and endodermal 
origin as well (116, 117). Following their isolation and expansion in vitro, lineage specific 
differentiation media is used to drive MSC’s toward different phenotypes. MSC’s derived from 
bone marrow, adipose, and umbilical cord tissues and their use as cell therapy for augmentation 
of the skeletal muscle injury response are discussed herein. 
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Bone Marrow-Derived Cells 
Bone marrow-derived MSC’s (BM-MSC’s) expand rapidly in culture from bone marrow 
aspirates, and like MSC’s from other sources have been shown to be pluripotent (110). It has 
been shown that, albeit to a small extent, endogenous circulating BM-MSC’s contribute to native 
skeletal muscle myofiber remodeling in healthy (118, 119) and injured muscle (120, 121). A 
study by Winkler and colleagues showed a dose-response correlation between the number of 
transplanted BM-MSC’s and the amount of functional recovery resulting from treatment by 
intramuscular injection within a skeletal muscle crush injury model (122). BM-MSC’s delivered 
to injured muscle via intravenous or intra-arterial injection may contribute to host angiogenesis 
and myogenesis (123, 124). Recently, studies have shown that many exogenous BM-MSC 
mediated cell-therapies have potentiated their positive effects through paracrine interactions with 
the host microenvironment rather than engraftment within host tissue (125, 126). 
Adipose-Derived cells 
Adipose tissue is now recognized as an abundant and readily accessible source of adult 
pluripotent cells. In adult mammals adipose tissue is composed of mesodermally derived 
adipocytes associated within a network of loose, areolar collagenous connective tissue. In 
addition to parenchymal tissue and in similar fashion to bone marrow, adipose tissue contains a 
stromal vascular cell population. Adipose tissues’ stromal vascular compartment is comprised of 
endothelial, smooth muscle, and progenitor cell populations (111). Following enzymatic 
digestion, the stromal cellular fraction can be separated from adipocytes and connective tissue 
and the resulting cell populations can be cultured in vitro. Tissue culture plastic adhering cells 
comprise the progenitor cell compartment and are commonly referred to as adipose derived stem 
cells (ADSC’s). In the presence of lineage specific inductive culture media, ADSC’s can 
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differentiate into adipogenic, chondrogenic, osteogenic, and myogenic cells (127). ADSC’s have 
been shown to spontaneously display myogenic potential in vitro and have been examined as 
potential donor cells aimed at augmenting skeletal muscle regeneration in vivo (128). For 
example, following injection into injured skeletal muscle, ADSC’s modulate inflammation, 
increase angiogenesis, and restore dystrophin expression in mouse models of muscular dystrophy 
(129). Kang and colleagues investigated the ability of ADSC’s to repair tissue damage in a 
murine ischemic hindlimb model (130). At four weeks post-injury and implantation, ADSC-
transplanted limbs showed increased vascular density and reduced muscle atrophy. Treated limb 
musculature was comprised of donor derived differentiated myocytes (130).  
Umbilical Cord Blood-Derived Cells 
As an alternative to bone marrow, human umbilical cord blood (UCB) has been explored as a 
source of MSC’s (114). Some data suggests UCB derived MSC’s posses a higher proliferative 
capacity when compared to BM-MSC’s or ADSC’s (131). Unlike bone marrow aspiration, 
human UCB is obtained by a simple and painless procedure after birth, ameliorating any ethical 
concerns. UCB derived MSC’s are pluripotent and some studies have shown that subpopulations 
of UCB cells display high myogenic potential (132). Injections of myogenic human UCB derived 
MSC’s have promoted myogenesis in mouse models of muscular dystrophy and hindlimb 
ischemia (133, 134). 
1.2.2.3. Limitations Associated with Cell-Therapy 
One limitation of cell-based therapies lies in the potential routes of administration. Typically, 
injected cells display an impaired ability to redistribute and do not migrate more than 200μm 
from the intramuscular injection site (85). The systemic delivery of cells via intravenous 
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injection has resulted in unintentional cell engraftment at sites such as the liver and spleen (76). 
Another limitation to cell-therapy-based strategies is the inadequate supply of fresh donor cells. 
Regardless of the auto- or allogeneic progenitor cell source (muscle derived, MSC, or others), 
cells typically must be expanded in culture to obtain an adequate cell number. Most cell therapy 
trials in skeletal muscle have utilized ex vivo expanded myoblasts, which most likely undergo 
culture-induced changes with associated deleterious effects upon the differentiation potential of 
the pre-transplanted cells. Consistent with this notion, a study by Montarras et al. reported that an 
ex vivo culture period of as little as three days, of satellite cells or myoblasts, negatively impacts 
their ability to contribute to skeletal muscle repair upon transplantation in vivo (135). Clonal 
assays comparing freshly isolated cells versus culture-expanded cells indicated that short-term 
culture decreases proliferative and differentiation potentials (135). A potential safety concern 
associated with the use of pluripotent MSC’s mediated cell therapy is the risk of 
transdifferentiation (136). It is now well accepted that some genes that confer pluripotency also 
confer oncogenicity. Studies determining the risk:benefit ratio associated with these cell-types 
are still in their infancy and need to be further studied prior to FDA consideration. These 
perspectives provide an overview of the significant hurdles to clinical translation. Perhaps the 
most significant limitation associated with cell-therapy approaches is the general poor 
engraftment of donor cells into host tissue (83, 84, 137-139).  
After over 3 decades of study, it is widely accepted that myogenic progenitor cell 
transplantation and stem cell transplantation typically does not result in a significant engraftment 
of donor cells into host tissue. It has also been demonstrated that the low number of viable 
engrafted cells are not typically correlated with the levels of functional improvement in host 
tissue. For these reasons, it is now widely accepted that favorable outcomes resulting from stem 
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and progenitor cell transplantation, whether alone or in the context of a TEMC, are most likely 
associated with a paracrine effect of the donor cells upon the host injured microenvironment 
(140-145). The release of cytokines or other signaling molecules by donor cells most likely play 
a role in the recruitment of host cells and/or the modulation of the host innate immune response. 
For example, many of the above myogenic cell types have been shown to secrete growth factors 
which, through their paracrine effects, have the potential to stimulate angiogenesis and modulate 
the host pro-inflammatory response (146-149). 
1.2.3. TEMC Approach 
Limitations associated with cell-based therapies provide the impetus for innovative tissue 
engineering approaches, which can augment the innate skeletal muscle response to injury. Since 
in vivo myogenic cells differentiate within a three-dimensional environment, one approach 
involves the incorporation of myogenic cells or precursor cells within an appropriate three-
dimensional biomaterial scaffold; i.e., a microenvironmental niche. A biomaterial scaffold in 
conjunction with a myogenic cell component is referred to as a tissue engineered muscle 
construct (TEMC). Ideal biomaterials for skeletal muscle engineering should be able to support 
the propagation and expansion of myogenic progenitor cells in vitro and also, for in vivo 
implantation purposes, be able to integrate into host tissue. Scaffolds with a variety of 
compositional and biological features have been developed. Although several studies have 
examined the efficacy of non-biodegradable scaffolds, such as phosphate-based glass (150), 
biodegradable scaffolds are preferred (151). Following in vivo implantation, biodegradable 
scaffolds promote host tissue integration, and have the potential to be replaced with host skeletal 
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muscle tissue (152). Both synthetic and natural biodegradable scaffolds have been examined as 
described below.  
1.2.3.1. Synthetic Scaffold Based TEMC 
The copolymer poly-lactide-co-glycolide (PLG) is FDA approved and has been used clinically as 
a source material for biodegradable sutures for more than 30 years (153). Biodegradable PLG 
has also been described as a suitable scaffold material that promotes cell adherence, proliferation 
and formation of new three-dimensional tissues (154, 155). Porous PLG scaffolds have also been 
shown to promote host mediated vascularization and cell infiltration upon their in vivo 
implantation (156). These characteristics suggest that PLG may hold potential as a biomaterial 
for TEMC’s. In a study by Thorrez et al., human skeletal muscle myoblasts were cultured within 
collagen coated porous PLG scaffolds and showed significant myogenic differentiation in vitro 
(157). However, when implanted subcutaneously in a mouse model after 4 weeks, these PLG 
based TEMC’s resulted in only 22% donor cell viability (157). Results showed that despite their 
incorporation within the scaffold, implanted cells were depleted due to host derived NK cells.  
Polymers composed of poly(ε –caprolactone) (PCL) and polylactic-co-glycolic acid 
(PGA) have also been examined as synthetic biodegradable three-dimensional scaffolds for 
skeletal muscle tissue engineering (158, 159). PCL based scaffolds with uni-directionally 
oriented nanofibers were able to promote muscle cell alignment and myotube formation (159). 
Following the implantation of neonatal rat myoblasts seeded onto PGA scaffolds, viable skeletal 
muscle and neo-vascularization could be identified within the TEMC at 45 days (158).  
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1.2.3.2. Naturally Occurring Scaffold Based TEMC 
TEMC’s have been created from naturally occurring scaffolds as an alternative to the above 
mentioned synthetic polymers. The extracellular matrix (ECM) consists of structural and 
functional molecules which support cell-cell interactions (160). For these reasons, most TEMC’s 
with a naturally occurring scaffold component are composed of ECM materials. 
Native ECM is composed of the secreted products of the resident cells of each tissue and 
organ within the body.  Furthermore, each tissue’s ECM contains a distinct structural and 
compositional blueprint of proteins, proteoglycans, glycosaminoglycans (GAG), and growth 
factors that are in a continuous state of dynamic reciprocity with the resident cells as 
microenvironmental conditions change (161).  The conventional role of ECM has been to 
provide mechanical support; however, the tissue specific composition and architecture of the 
ECM also plays a central role in directing cell communication and behavior by providing an 
instructive ligand landscape (162, 163).  A preferred tissue engineered biomaterial would 
preserve these characteristics to effectively promote tissue remodeling. Most naturally occurring 
scaffolds used in TEMC design consist of components of ECM or whole mammalian ECM itself. 
Collagen I Based TEMC’s 
Type I collagen is the predominant component of the ECM and represents the most 
abundant protein within mammalian tissue (164). As a substrate in vitro, collagen I can enhance 
the viability and proliferation of myogenic progenitor cells (165, 166). TEMC’s collagen I based 
scaffolds have been injected as hydrogels and as implanted as three-dimensional scaffolds (167, 
168). In several studies, the implantation of a myoblast-collagen I based TEMC within a VML 
injury model was associated with a minimal inflammatory response and a donor cell contribution 
that enhanced host-mediated myogenesis (169, 170). In a head-to-head comparison, when 
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implemented within a DMD mouse model, a collagen I TEMC seeded with myogenic precursor 
cells restored dystrophin more efficiently when compared to cell-therapy-alone based injections 
of the same cells (171).   
Hyaluronic Acid Based TEMC’s 
Hyaluronic Acid (HA) is a major component of the ECM and has been shown to have 
biologic activity including the ability to promote angiogenesis and prevent apoptosis (172). 
Myoblasts seeded within a three-dimensional HA based culture system were able to proliferate 
and fuse (173). In a study by Rossi and colleagues, satellite cells and myoblasts were 
incorporated into a photo-cross-linked HA-based hydrogel and delivered to injured skeletal 
muscle in a pre-clinical model of VML (174). This HA-based TEMC resulted in functional 
recovery as assessed by contractile force measurements and was associated with the formation of 
new neural and vascular networks.  
Decellularized Mammalian Whole- ECM Based TEMC’s 
While individual purified components of the ECM such as collagen I and HA have been 
used as substrates or vehicles for cell delivery, the most extensively investigated naturally 
occurring scaffold in TEMC design is decellularized native mammalian tissue; i.e., ECM.  
Acellular ECM scaffolds are essentially free from DNA and xenogeneic and antigenic epitopes 
when manufactured by methods that meet stringent criteria (175), and therefore will not elicit an 
adverse immune response.  A three-dimensional matrix derived by decellularization of skeletal 
muscle or other native mammalian tissue may be advantageous because the differentiation of 
myogenic progenitor cells can be influenced by natural tissue specific factors including the three-
dimensional ultrastructure, surface ligands, and chemical and mechanical microenvironment 
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(176, 177).  Myoblasts cultured on ECM derived from skeletal muscle showed enhanced growth 
rates and differentiation potentials compared to myoblasts on tissue culture plastic (178). These 
data supports the use of intact ECM scaffolds as a suitable substrate for TEMC’s. In a study by 
Merritt et al., a rat model of VML injury was repaired with a TEMC composed of bone marrow 
derived MSC’s seeded onto an acellular muscle ECM scaffold. The construct was implanted into 
injured gastrocnemius muscles and showed the presence of vascularized regenerating skeletal 
muscle after 42 days. In addition, the TEMC repaired muscle was associated with a partial 
functional recovery (179).   
 Studies have shown that a conditioning period of in vitro mechanical loading 
upon whole ECM TEMC’s can affect the biologic properties of the scaffold and influence 
myogenesis and improve cell-scaffold integration prior to transplantation (180-182). 
Vandenburgh et al. conducted pioneering work in which a mechanical cell stimulator device 
applied mechanical stimulation to a TEMC composed of skeletal muscle myoblasts incorporated 
into a Matrigel:collagen scaffold (183). This approach resulted in improved myofiber diameter 
and alignment, increased elasticity of the muscle fibers, and improved cell-generated passive 
force compared to static cultures. A study by Borschel et al. showed that TEMC’s composed of 
skeletal muscle myoblasts seeded onto decellularized muscle scaffolds produced specific forces 
that were approximately 5% of that observed for the native muscle after 3 weeks of culture 
(184). In a similar fashion, Christ and colleagues seeded primary human muscle precursor cells 
onto acellular bladder submucosa and subjected the constructs to cyclic strain for up to 4 weeks, 
followed by subcutaneous implantation of the cell-seeded construct within the latissimus dorsi 
muscle of mice. This study showed that specific forces of 1% of that observed for native 
latissimus dorsi were produced when the constructs were preconditioned in an in vitro bioreactor 
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(182). Although the observed maximal contractility was only 1% of that of native muscle, this 
result was still 75-fold greater than in previous reports (182). 
Limitations Associated with TEMC’s 
The formation of TEMC’s through the incorporation of myogenic cells into biomaterial 
scaffolds has, as discussed above, been occasionally able to enhance donor cell viability and 
myogenicity. Many limitations associated with TEMC cell-scaffold integration have been at least 
partially resolved by the practice of ex vivo mechanical loading prior to implantation.  However, 
the practical and regulatory hurdles associated with the TEMC approach will limit clinical 
translation in the near term. Because TEMC’s involve the use of a cellular component, the same 
challenges associated with pure cell-based therapies apply. 
1.2.4. Acellular Scaffold Approach 
Limitations associated with the use of a cell-based therapy, including the TEMC approach, 
provide the stimulus for alternative cell-free approaches. The use of decellularized tissues as 
(acellular) ECM bioscaffolds has been explored as a therapeutic approach for functional skeletal 
muscle reconstruction.  The approach is based upon the concept of the ECM providing an 
instructive and conducive microenvironment that can modulate the default scar tissue response to 
injury toward a constructive regenerative response. Obviously for such a cell-free based 
approach to be viable, endogenous cells must serve as the source of myogenic precursors. 
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1.2.4.1. Implanted Acellular ECM Scaffolds Influence the Host Tissue 
Microenvironment 
The in vivo placement of an ECM bioscaffold affects the injured tissue response by several 
mechanisms including: 1) provision of an ultrastructure environment that is cell-friendly (28, 33, 
185, 186), 2) release of bound growth factors, chemokines and cytokines during the process of 
degradation (15, 173), 3) release of bioactive cryptic peptides generated by the degradation of 
matrix parent molecules (7-10, 15, 23, 186-192), and 4) modulation of the host innate immune 
response toward a regulatory and constructive phenotype (21, 22, 193). 
Preclinical and clinical examples of these processes have been shown in a number of 
tissues including esophagus (194, 195), lower urinary tract (196, 197), myocardium (198, 199), 
and skeletal muscle (32, 200-207) among others.  The natural tendency of skeletal muscle to 
regenerate following mild injury involves a temporally orchestrated series of similar events that 
have been recently reviewed by Tidball (57).  Stated differently, the use of acellular matrix 
scaffolds appears to provide an environment that augments the natural response of skeletal 
muscle to injury including activation, recruitment and differentiation of endogenous 
stem/progenitor cells and minimization of a prolonged pro-inflammatory reaction. 
1.2.4.2. Process of Acellular ECM Scaffold Remodeling 
Biologic scaffolds composed of ECM are rapidly infiltrated by host polymorphonuclear and 
mononuclear cells in vivo, which initiate the scaffold degradation process. Macrophages, in 
particular, are key facilitators of this degradation, as their depletion prevents the degradation of 
ECM scaffolds (31).  Quantitative studies of 14C-labeled ECM scaffolds show that approximately 
50% of the ECM scaffold is degraded after 28 days and virtually all of the ECM is replaced with 
host tissue by 60 - 90 days post-implantation (23, 191, 192); a process partially dependent upon 
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the anatomic site of placement. The degradation of ECM scaffolds in vivo is critical to the 
constructive remodeling process (5-8, 186). Degradation of ECM generates cryptic oligopeptides 
with potent in vitro and in vivo bioactivity not present in the parent ECM molecules.  These 
“matri-cryptic” peptides have shown chemotactic activity for a number of stem/progenitor cells 
in vitro and have been shown to induce the endogenous recruitment of host progenitor cells in 
vivo (5, 11, 27, 186, 200, 208-210). A large number of these multipotential cell-types influenced 
by the degradation products of ECM scaffold, both in vitro and in vivo, have myogenic potential 
(Figure 2). 
 
 
Figure 2: The Implantation of an Acellular ECM Scaffold Promotes the Recruitment of Host Cells. Upon their 
implantation into areas of skeletal muscle injury (A), ECM scaffolds are subjected to rapid host-mediated proteolytic 
degradation (B). The degradation process releases cryptic peptides, which influence the local tissue 
microenvironment, including the recruitment of distinct populations of myogenic cells (C). The implantation of 
acellular ECM scaffolds ultimately results in constructive tissue remodeling, characterized by the formation of site-
appropriate and functional tissue (D). 
1.2.4.3. Acellular ECM Scaffolds Recruit Progenitor Cells 
The accumulation of potentially therapeutic progenitor cells into sites of injury, whether 
administrated via direct injection (cell based approach) or implanted in context with a TEMC, is 
associated with several limitations including the poor engraftment of donor cells into host tissue. 
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However, the in vivo recruitment of endogenous stem/progenitor cells may partially obviate this 
limitation, either because of the selection of appropriate precursor cells and/or the lack of 
external manipulation of the cells.  Matrix generated chemotactic peptides have been shown to 
be chemotactic for several distinct populations of myogenic stem and progenitor cells in vitro 
including: multipotential progenitor cells (186); Sox2+ cells (27); skeletal muscle myoblasts 
(210) ; and multipotent perivascular progenitor cells (5, 11, 33, 208). Endogenous cells with 
myogenic potential have been recruited to sites of ECM scaffold implantation and degradation in 
vivo. For example, endogenous CD133+ progenitor cells (200, 209), multipotent perivascular 
progenitor cells (211), and BM-MSC’s (28, 32, 212) have been recruited to sites of ECM 
implantation within pre-clinical models of skeletal muscle VML. These same cells have 
previously been used, with limited success, as cell sources for exogenous cell-therapy and in the 
context with scaffolds as TEMC’s (Figure 3) ECM scaffolds have also been shown to recruit 
CD34+ progenitor cells (209), Sox2+, Sca1+, Rex1+ progenitor cells (5), and cardiomyocytes 
(213, 214) upon their implantation in vivo. These results show the ability of acellular ECM 
scaffolds to induce endogenous cell-therapy and recruit progenitor cells to sites of injury. 
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Figure 3: Common Populations of Cells with Myogenic Potential Employed In Exogenous Cell-Therapy, 
Exogenous Tissue Engineered Muscle Construct (TEMC) Therapy, and Acellular ECM Scaffold Mediated 
Endogenous Cell Recruitment. Several ideal cell-types investigated for exogenous cell-therapy are recruited 
endogenously by ECM scaffolds. 
1.2.4.4. Acellular ECM Scaffolds Influence the Host Innate Immune Response 
The innate immune system has recently been shown to play a pivotal role in both the activation 
and propagation of the inherent regenerative response of skeletal muscle (57). Following injury, 
a heterogeneous population of responding macrophages is necessary for muscle’s regenerative 
plasticity (57). Specifically, after injury a population of cells consisting primarily of pro-
inflammatory (M1) macrophages not only facilitates pathogen control and debris clearance, but 
also stimulates the activation of quiescent muscle satellite cells (215, 216). For efficient 
regeneration and restoration of function, at 48 hours after injury, the primary cell population 
responding to skeletal muscle injury must be composed of constructive (M2) macrophages (217). 
M2 macrophages are essential in propagating the inherent regenerative response of skeletal 
muscle by promoting myogenesis (215, 218). 
As stated above, interventions with a cellular component are plagued by the lack of donor 
cell engraftment are typically associated with less than favorable outcomes. However, limited 
positive results of cell-based interventions have been associated with donor cell-mediated 
production of soluble factors capable of affecting the host innate immune system (219-221). 
Similar to these paracrine effects, acellular ECM scaffolds, upon their implantation in vivo, have 
been shown to influence the local host innate immune response. Specifically, correctly prepared 
ECM scaffolds promote the constructive M2 macrophage phenotype (21, 22). The ECM 
scaffold-mediated predominant M2 macrophage response is associated with constructive 
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remodeling outcomes downstream of the initial participation of the innate immune system (173, 
222). Stated differently, ECM scaffolds induce host constructive macrophages and result in 
favorable remodeling outcomes. 
1.2.4.5. Limitations Associated with Acellular ECM Scaffolds 
Outcomes resulting from preclinical and clinical applications of acellular ECM scaffolds have 
varied considerably and have ranged from poor to excellent (195, 223-228). A potential 
explanation for these discrepancies may lie within the preparation methods for such materials. 
For example, numerous decellularization strategies exist for each source tissue; all varying in 
their effectiveness of removing cellular material as well as altering the ECM structure and 
composition. Effective decellularization with preservation of native structure function 
relationships of the component ECM molecules has been shown to be critical for in vivo 
constructive remodeling outcomes (229). For example, in vivo implantation of biologic scaffold 
materials with notable residual DNA amounts was directly correlated to a negative host response 
(229). Thus, the clinical performance of biologic scaffolds is largely dependent on the 
preparation and processing techniques.  
1.2.4.6. Clinical Translation of ECM Scaffolds 
Biologic scaffolds are commonly used as an alternative to synthetic scaffolds in tissue 
engineering and regenerative medicine applications (195, 200, 202-206, 230, 231). There exist 
numerous commercially available ECM based products which are derived from a variety of 
species including human, porcine, and bovine; as well as an array of tissue sources such as small 
intestinal submucosa (SIS), urinary bladder, dermis, pericardium, heart valves, and peritoneum, 
among others.  
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More than 4 million patients have been implanted with an ECM scaffold for a variety of 
conditions including: hernia repair (232, 233), diabetic ulcers (234, 235), rotator cuff repair (236-
238), breast reconstruction (239, 240), musculotendinous reinforcement (201), pelvic floor 
reconstruction (241, 242), and urologic defects (243, 244), among others.  
A recent clinical case study highlighted the ability of an acellular ECM scaffold to 
promote skeletal muscle constructive remodeling within a wounded soldier suffering from VML 
of the quadriceps femoris muscle (201). At 16 weeks post-implantation, the patient showed a 
30% increase in muscle function that was concomitant with the presence of soft tissue 
resembling skeletal muscle on CT.  
A clinical study is in progress which evaluates the effect of ECM implantation at the site 
of VML in 80 patients. The outcome measures of this trial include mechanical strength and 
function, the cell populations involved in the process, quality of life in these patients, as well as 
to examine the cellular composition of the remodeled tissue.  Preliminary results show the 
presence of multipotent perivascular cells, desmin+ skeletal muscle cells, neovascularization, 
and regenerating skeletal muscle tissue (centrally located nuclei) widely distributed throughout 
the remodeling ECM (245). Furthermore, at 16 weeks post-operatively theses patients have 
exhibited at least a 20% increase in strength compared to pre-ECM implantation values 
[Unpublished data]. Taken together, these results demonstrate the potential clinical efficacy of 
ECM scaffolds in promoting the recruitment of perivascular progenitor cells and facilitating 
restoration of structure and function in volumetric skeletal muscle defects. 
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1.2.5. Conclusions 
Tissue engineering and regenerative medicine approaches aimed at augmenting the regenerative 
response of skeletal muscle to injury have included both cell-based and acellular strategies. The 
cell-based interventions face significant hurdles to clinical translation including poor donor cell 
viability, engraftment, migration and regulatory challenges among others. Acellular strategies 
include the use of ECM scaffolds, which constructively influence the host injured skeletal 
muscle microenvironment. ECM scaffolds are presently FDA approved for many clinical 
applications and have been shown to recruit enodgenous myogenic progenitor cells to sites of 
injury and implantation. Although cell based and acellular approaches have not been compared 
in head to head studies, it is clear that each approach pros and cons that are worthy of 
consideration. In the near term, acellular approaches may be preferable because of their existing 
regulatory approval. Moreover the studies presented in the present dissertation show further 
mechanisms of action behind the favorable remodeling outcomes associated with ECM 
bioscaffolds. 
1.3. THE ROLE OF THE INNATE IMMUNE SYSTEM FOLLOWING SKELETAL 
MUSCLE INJURY 
Macrophages are a plastic cell population capable of acquiring diverse phenotypes. They can be 
classified as either classically activated and pro-inflammatory (M1) or alternatively activated and 
immunomodulatory (M2) (46-49, 246). Classically activated macrophages, designated M1 after 
the T cell Th1/Th2 nomenclature, produce pro-inflammatory cytokines and reactive oxygen 
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intermediates; and are responsible for pathogen killing, cell clearance, and the general 
propagation of a pro-inflammatory response (46). Alternatively activated macrophages, 
designated M2, deposit collagen; produce anti-inflammatory cytokines; and facilitate tissue 
remodeling and repair (247). Although histologically indistinguishable, M1 and M2 
macrophages can be identified and distinguished by their species specific and distinct cytokine, 
gene expression, and cell surface marker profiles (47, 248). Classically activated, pro-
inflammatory (M1) macrophages are activated by IFN-γ alone or in combination with LPS or 
TNF. M1 macrophages express IL-12high, IL-23high, IL-10low and produce high levels of inducible 
nitric oxide synthase (iNOS). They also secrete pro-inflammatory effector molecules and 
cytokines such as reactive oxygen species and IL-1β, IL-6, and tumor necrosis factor (TNF). 
These pro-inflammatory products are inducers of Th1 type inflammatory responses {Mantovani, 
2005 #135}. In contrast, M2, alternatively activated, macrophages are activated by 
immunomodulatory cytokines such as IL-4, IL-13, and IL-10, and glucocorticoid or secosteroid 
(vitamin D3) hormones. M2 activated macrophages express IL-12low, IL-23low, and IL-10high and 
express high levels of scavenger, mannose, and galactose receptors. M2 macrophages and are 
involved in polarized Th2 reactions (46). 
The role of a heterogeneous host macrophage response to injury has recently been 
reviewed (57, 249, 250). Immediately following acute skeletal muscle injury, pro-inflammatory 
cytokines polarize responding host macrophages towards a predominant M1 phenotype. To 
facilitate appropriate skeletal muscle regeneration, a shift in macrophage polarization takes place 
and after approximately three days macrophages within the injury site display a predominant M2 
phenotype (22). Furthermore, when an M2 macrophage response is inhibited, the host injury 
response is characterized by a severe lack of muscle regeneration and an accentuation of 
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inflammation and necrosis (217). In the context of biomaterial implantation, recent studies have 
shown that a predominant M2 macrophage response to degradable biologic scaffolds is 
associated with a constructive remodeling outcome. Conversely, a predominant M1 response 
typically correlates with a foreign body response, the presence of foreign body giant cells, and a 
poor remodeling outcome in non-degradable biologic scaffolds (22, 31). 
1.4. AGE-ASSOCAITED PATHOLOGIES AFFECTING THE SKELETAL MUSCLE 
INJURY RESPONSE 
Sarcopenia (from the Greek meaning "poverty of flesh") is the degenerative loss of skeletal 
muscle mass and strength in senescence. In the United States alone, approximately one third of 
women and two-thirds of men older than age 60 have sarcopenia (251). The direct healthcare 
cost of sarcopenia in the U.S. has been estimated at over $18.5 billion annually (252). The 
morbidity of sarcopenia is associated not only with the degenerative loss of muscle mass, but 
also with an impaired regenerative response to skeletal muscle injury (253). With age and the 
associated loss of inherent regenerative capacity, injured skeletal muscles are replaced with scar 
and connective tissue (254, 255). This impaired regenerative response complicates treatment 
options and orthopedic procedures in elderly individuals.  
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1.4.1. Age-Related Changes in Skeletal Muscle Myogenesis 
With age, there is a gradual decline in the regenerative response of skeletal muscle to injury 
(256). The decline is associated with satellite cell and myoblast dysfunction (257). This decrease 
in satellite cell function with age is caused by a decline in extrinsic microenvironmental cues 
rather than a decrease in satellite cell pool (258, 259). In addition, parabiotic studies revealed that 
exposure to a young systemic milieu resulted in increased satellite cell activation and subsequent 
rejuvenation of the age-impaired skeletal muscle regenerative niche(260). Thus it appears that 
the loss of myogenic potential of aged satellite cells is reversible and therefore mediated via 
partially extrinsic cues within the regenerative microenvironment. 
1.4.2. Age-Related Changes in Macrophage Physiology  
Immunosenesence associated with advanced age negatively impacts the innate immune system 
(261, 262). Specifically, the effect of aging on macrophages appears to be multifaceted and 
affects many different macrophage functions. Aged subjects display defects in various signaling 
pathways affecting diverse macrophage activity (263-265). Macrophages from aged humans and 
mice display a reduced capacity for chemotaxis and phagocytosis (266-270). These functional 
defects cause an inefficient clearance of apoptotic muscle fiber and tissue debris, resulting in 
decreased myogenesis in response to injury. In addition, evidence suggests that age-impaired 
macrophages display a decreased production of cytokines (264, 271-273). Like their younger 
counterparts macrophages derived from aged subjects can also be exogenously polarized, 
however requiring higher concentrations of polarizing factors. (274). These reports suggest an 
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impairment in the susceptibility for polarization in macrophages from aged subjects (275) and 
therefore an altered myogenic response to skeletal muscle injury.  
1.5. CENTRAL HYPOTHESIS 
The central hypothesis of the present dissertation states: bioscaffolds composed of extracellular 
matrix mitigate age-related changes to the skeletal muscle injury microenvironment through 
modulation of macrophage phenotype and increased myogenic progenitor cell activation.  
1.6. SPECIFIC AIMS 
Aim 1: To evaluate the host remodeling response, including macrophage phenotype induced by 
extracellular matrix (ECM) scaffolds derived from young and aged source animals. 
 
Aim 2: To determine the ability of ECM to enhance the polarization of macrophages isolated 
from young and aged subjects. 
 Sub-Aim: To evaluate the effect of ECM and polarized macrophages upon the 
chemotaxis, mitogenesis, and differentiation of skeletal muscle progenitor cells. 
 
Aim 3: To determine if an ECM scaffold induced progenitor cell participation and constructive 
macrophage phenotype correlate with a constructive tissue remodeling outcome in a mouse 
model of volumetric muscle loss (VML). 
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2.0 THE HOST REMODELING RESPONSE, INCLUDING MACROPHAGE 
PHENOTYPE INDUCED BY ECM SCAFFOLDS DERIVED FROM YOUNG AND 
AGED SOURCE ANIMALS  
2.1 BACKGROUND 
Biologic scaffolds composed of xenogeneic extracellular matrix (ECM) are derived by the 
decellularization of mammalian tissues and have been used in both preclinical and clinical 
settings for the reconstruction of damaged or missing tissues (195, 201, 276). ECM scaffolds can 
alter the default wound healing response from the well described pro-inflammatory and scarring 
events toward a more constructive remodeling response, i.e., the site appropriate formation of 
functional tissue, in a variety of anatomic locations including dermis (277), esophagus (278, 
279), skeletal muscle (202, 276, 280), and heart (213, 214, 281), among others. Results of such 
clinical applications have varied considerably (195, 223-228), and the variables which affect 
outcome are only partially understood. Two intuitively important determinants of the remodeling 
outcome are the physical and biologic properties of the ECM scaffold material itself, and the 
innate immune response of the recipient. Modulation of macrophage phenotype, a critical 
component of the innate immune response, has been shown to play a prominent role in the 
scaffold remodeling outcome (21, 22), but the effect of the age of tissue from which the ECM 
scaffold is prepared has been largely ignored. 
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 Mammalian fetal wound healing is characterized by site-specific regeneration and 
minimal scar tissue formation; a distinct contrast to wound healing in adults (282). This tissue 
regeneration response is associated with selected pro-inflammatory events (283, 284), increased 
capacity for wound closure (285, 286), and a distinct ECM composition (287-290). The ECM 
present in fetal tissues is enriched in glycosaminoglycans which facilitate the proliferation and 
migration of a number of cell types (287, 291, 292). The collagen content of fetal ECM is less 
mature and contains fewer cross-links when compared to adult ECM (293). Minimal collagen 
cross-linking facilitates rapid ECM turnover and remodeling. Because of these characteristics, it 
is plausible that biologic materials derived from neonatal or newborn tissues may be better suited 
as inductive scaffolds than biologic scaffold materials derived from older animals. 
The diverse remodeling outcomes associated with ECM scaffold use can also be 
attributed to variables such as processing methods (202), source species and tissue origin of the 
ECM (294), post-implantation mechanical load (295), and decellularization efficacy (229). 
Because the response to tissue injury is known to be more favorable and robust in young vs. aged 
mammals, some biologic scaffolds use source materials that include ECM derived from fetal 
cells or mammals (296, 297). It has been previously reported that distinct differences exist in the 
mechanical, structural, and in vitro biologic properties of ECM harvested from different aged 
animals (208) (Table 1). However, the effect of donor animal age upon the in vivo remodeling 
characteristics of xenogeneic ECM scaffolds has not been systematically examined. 
The objective of the present chapter was to compare the in vivo remodeling outcome of 
ECM scaffolds that differ only in source animal age. An established rodent model of abdominal 
wall muscle reconstruction [18, 39] was used to evaluate the host remodeling response, including 
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the phenotype of responding macrophages, scaffold induced vascularity, innervation, and 
myogenesis over time, and the mechanical properties of the remodeled injury site after 26 weeks. 
 
Table 1: A summary of the pre-implantation properties of the differently aged ECM scaffolds. Adapted from 
Tottey et al, 2011 with permission. 
 
 
1.7. MATERIALS AND METHODS 
2.1.1 Overview of Experimental Design 
Small intestinal submucosa (SIS) ECM was prepared from the small intestine of 4 distinctly 
different aged pigs of identical gene pool and husbandry: 3 weeks (neonatal), 12 weeks (feeder), 
26 weeks (market), and greater than 52 weeks of age (sow). The different aged tissues were 
collected, decellularized, and processed at the same time using identical methods and the 
resulting SIS-ECM was used to repair a 1.0 cm by 1.0 cm partial thickness abdominal wall 
musculature defect in a Sprague-Dawley rat model. Treatment groups were equally and 
randomly subdivided and sacrificed at 14, 28, 120, or 180 days post-surgery. Following 
euthanasia and explantation of the remodeled scaffold materials, mechanical testing and 
histologic and immunolabeling methods were used to determine the mechanical and morphologic 
characteristics of the remodeled tissue (Table 2). 
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 Table 2: Tissue assessment. All samples received Massons's trichrome and vasculature (CD31) staining with 
associated histologic assessment (×). Staining for macrophages was done at a time point consistent with a robust 
host macrophage response (14 days). Mechanical testing, along with staining for muscle fiber phenotype (myosin) 
and innervation (β-tubulin III), was included where trichrome staining confirmed the presence of skeletal muscle 
within the defect site (180 days). 
 
 
2.1.2 Source and preparation of ECM scaffold material 
The jejunum from Whiteshire Hamroc pigs of 4 distinctly different ages (3, 12, 26 and >52 
weeks) were harvested immediately following euthanasia (Tissue Source, Lafayette, IN). The 
animals were of identical genetic heritage, and were raised and kept in identical husbandry 
conditions including diet and vaccination history. All tissues were harvested on the same day and 
stored on ice prior to processing to create SIS-ECM as previously described (3, 298). Briefly, the 
intestines were rinsed with water and the mesenteric tissues were removed. The intestines were 
cut longitudinally and mechanically delaminated to remove the tunica serosa, tunica muscularis 
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externa, and the luminal portion of the tunica mucosa including most of the lamina propria. After 
delamination, the tunica submucosa and the basilar layer of the tunica mucosa including the 
muscularis mucosa and the stratum compactum of the lamina propria remained. The material was 
further decellularized using 0.1% peracetic acid (Rochester Midland Corporation, Rochester, 
NY) followed by multiple rinses with saline and deionized water as previously described (298). 
The SIS-ECM material was then vacuum pressed to form 4-layer constructs and cut to 1 cm2 in 
size before being terminally sterilized with ethylene oxide. 
2.1.3 Surgical procedure 
All procedures were performed in accordance with the National Institute of Health (NIH) 
guidelines for care and use of laboratory animals, and with approval of the Institutional Animal 
Care and Use Committee (IACUC) at the University of Pittsburgh. Adult female Sprague-
Dawley rats weighing approximately 300 g (Charles River Laboratory, Wilmington MA) were 
subjected to partial thickness abdominal wall defect surgery (22, 31). Animals were separated 
into groups based on treatment type: (1) uninjured control, (2) untreated defect, (3) autologous 
tissue graft (excised and immediately replaced oblique musculature), (4) sow aged scaffold (>52 
weeks), (5) market aged scaffold (26 weeks), (6) feeder aged scaffold (12 weeks), (7) neonate 
aged scaffold (3 weeks); and harvest time point: 14, 28, 120 and 180 days (n = 3 body walls per 
treatment group at 14, 28, and 120 days; n = 8 body walls per treatment group at 180 days; 119 
total surgeries were perfomed).  Five implant sites per treatment group were used for mechanical 
testing at 180 days only, and three implant sites per treatment group were used for histologic 
analysis at each time point. 
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Each animal was anesthetized with 2% isoflurane in oxygen and the ventral abdomen was 
prepared by hair clipping and scrubbing with Betadine (povidone-iodine) before the placement of 
sterile drapes around the surgical site. A ventral midline abdominal skin incision was created. 
The subcutaneous tissues were bluntly dissected from the underlying muscle tissues on one side 
of the midline for a distance of approximately 4 cm to the anterior axillary line exposing the 
oblique musculature. A 1.0 cm2 partial thickness defect consisting of the internal and external 
oblique layers of the abdominal wall musculature was excised while leaving the underlying 
transversalis fascia and peritoneum intact. The defect was left untreated or repaired with a 1.0 
cm2 piece of the chosen test article. A single 4-0 prolene suture was placed at each of the four 
corners of the test article to secure it to the adjacent abdominal wall musculature, allowing it to 
be exposed to a physiologic mechanical load and identifying the boundary of the implant at the 
time of necropsy. Interrupted subcuticular 4-0 Vicryl suture was used for skin closure. Each 
animal was allowed to recover from anesthesia on a heating pad and was returned to the housing 
unit. 
Each animal received 0.06 mg Buprenex (buprenorphine hydrochloride) by subcutaneous 
injection the day of surgery and for two additional days. Baytril (5 mg) was given orally the day 
of surgery and for two additional days. The dietary habits, general health status, and the surgical 
site were monitored daily and recorded. 
2.1.4 Euthanasia and specimen harvest 
Animals were sacrificed at 14, 28, 120, or 180 days. Each rat was euthanized with 5% isoflurane 
in oxygen followed by an intracardiac injection of 5 mL of potassium chloride to induce cardiac 
arrest. Implants for histologic evaluation (n = 3), including ~2 mm of surrounding native 
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abdominal wall musculature, was excised, mounted on corkboard to maintain in situ size and 
shape, and placed in 10% neutral buffered formalin. Implants for mechanical testing (n = 5) were 
placed in Ringer’s solution immediately after excision for uniaxial tensile testing. 
2.1.5 Histologic and immunolabeling analysis 
The tissue was embedded in paraffin, cut into 5-um thick sections, and mounted onto glass slides 
before being stained with Masson’s trichome. The primary antibodies used for the 
immunolabeling studies were: (1) monoclonal anti-myosin (skeletal, slow, clone NOQ7.5.4D; 
Sigma Aldrich, St. Louis, MO) at 1:4000 dilution for identiﬁcation of slow (type I) skeletal 
muscle ﬁbers; (2) monoclonal anti-myosin (skeletal, fast, alkaline phosphatase conjugate, clone 
MY-32, Sigma Aldrich) at 1:200 dilution for identiﬁcation of fast (type II) skeletal muscle ﬁbers; 
(3) rabbit polyclonal CD31 (Abcam, Cambridge, MA) at 1:100 dilution for identiﬁcation of 
endothelial cells; (4) anti Beta-III Tubulin (Dako USA, Carpinteria, CA) at 1:200 dilution for 
identiﬁcation of neurons; (5) goat polyclonal CD206 (Santa Cruz Biotech, Santa Cruz, CA) at 
1:100 for identification of M2 macrophages; (6) rabbit monoclonal CCR7 (Epitomics, 
Burlingame, CA) at 1:100 for identification of M1 macrophages; and (7) mouse-anti rat CD68 
(Serotec, Raleigh, NC) at 1:50, as a pan macrophage marker. Table 2 shows the details of the 
specific staining performed at each time point. 
To identify fast and slow muscle fibers, unstained sections were deparafﬁnized and heat-
mediated epitope retrieval was performed with 0.1 mM EDTA buffer at 95-100 oC for 25 min 
followed by enzyme-mediated antigen retrieval with 0.1% trypsin/0.1% calcium chloride 
digestion at 37 oC for 10 min. Slides were washed in Tris buffered saline (TBS), pH 7.6, then 
incubated for 10 min in a blocking solution containing 0.1% Tween 20, 0.1% Triton X, 2% 
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normal horse serum and 2% normal goat serum at room temperature to prevent non-speciﬁc 
antibody binding. To inhibit endogenous peroxidase activity, the slides were incubated with 3% 
hydrogen peroxide (Spectrum, New Brunswick, NJ) in methanol for 10 min at room temperature. 
The slow anti-myosin antibody was applied and incubated for 30 min at room temperature. The 
slides were then incubated with the secondary antibody (biotinylated anti-rabbit; Vector) at 1:200 
for 30 min at room temperature, followed by horseradish peroxidase solution (Vector) for 30 min 
at 37 oC. Diaminobenzidine (DAB) (Vector) was applied to detect positive staining cells. The 
blocking solution was then applied again for 10 min at room temperature, followed by the fast 
anti-myosin antibody for 60 min at room temperature. Red alkaline phosphatase substrate was 
applied to detect positive staining (Vector). 
For Beta-III Tubulin immunolabeling, slides were deparrafinized, and heat-mediated 
epitope retrieval was performed as described above. The slides were washed in phosphate 
buffered saline (PBS) then incubated for 30 min with 2% normal horse serum (Vector) at 37 oC 
to prevent non-speciﬁc antibody binding. Endogenous peroxidase activity, was inhibited by 
incubating with 3% hydrogen peroxide (Spectrum) in methanol for 30 min at room temperature. 
The tissue sections were then incubated in the Beta-III tubulin primary antibody for 1 hour at 
room temperature, followed by the secondary antibody (biotinylated anti-mouse; Vector) at 
1:200 for 30 min at room temperature. Horseradish peroxidase solution (Vector) was applied for 
30 min at 37 oC, and diaminobenzidine (DAB) (Vector) was used to detect positive staining 
cells. The slides were counterstained with hematoxylin. 
Similarly, for CD31 immunolabeling the slides were deparaffanized and heat-mediated 
epitope retrieval was performed with 0.01 M citrate buffer (Spectrum), pH 6.0, at 95-100oC for 
20 min. Enzyme-mediated antigen retrieval was then performed using proteinase K in a buffer of 
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50 mM Tris base and 1 mM EDTA, pH 8.0, at 60oC for 10 min. Following washes in PBS, the 
slides were incubated for 60 mins with 2% normal horse serum (Vector) at 37oC to prevent non-
speciﬁc antibody binding, followed by a 30 minute incubation in 3% hydrogen peroxide. The 
tissue sections were then incubated in the CD31 primary antibody for 1 hour at room 
temperature, followed by the secondary antibody for 30 min at 37oC. Horseradish peroxidase 
solution (Vector) was applied for 30 min at 37oC. Diaminobenzidine (DAB) (Vector) was used 
to detect positive staining cells and the slides were counterstained with hematoxylin. 
 M1 vs. M2 polarized macrophages were identified by immunolabeling.  After 
deparafﬁnization, heat-mediated antigen retrieval was performed with 0.01 M citrate buffer 
(Spectrum), pH 6.0, at 95-100oC for 20 min. Tissue sections were incubated in blocking buffer 
(1% bovine serum albumin/0.05% Tween-20/0.05% Triton X-100) for 1 hour. The primary 
antibodies (CD206, CCR7, and CD68), diluted in blocking buffer, were then added to the slides 
for 16 hours at 4°C in a humidified chamber.  The secondary antibodies (also diluted in blocking 
buffer) were incubated on the slides for 1 hour in a humidified chamber at room temperature. 
The secondary antibodies used were Alexa Fluor® goat anti-rabbit 568 (Invitrogen), Alexa 
Fluor® donkey anti-goat 488 (Invitrogen) and Alexa Fluor® donkey anti-mouse 350 
(Invitrogen). Draq5 (Cell Signaling Technologies, Danvers MA) was used as a nuclear 
counterstain. 
2.1.6 Quantification of histologic and immunolabeling analysis 
All tissue sections were imaged using a Zeiss Axio Observer Z1 or Nikon E600 microscope with 
Nuance multispectral imaging system (CRI Inc, Cambridge MA) with appropriate brightfield and 
fluorescent filter sets. Three random Masson stained images of the device implant site at the 
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interface with native tissue were taken at 100x magnification. A quantitative analysis of the 
trichrome staining was conducted by dertermining the percent of blue stained tissue within the 
surgical site using the Nuance software. Collagen or connective tissue (blue) and nuclei or 
muscle fibers (red) were isolated by spectral filtration and subsequent thresholding. High percent 
blue staining indicates the predominant presence of collagenous connective tissue.  
Quantification of M1/M2 polarization was achieved using a custom image analysis 
pipeline developed using the cell profiler image analysis package (299, 300). This custom 
pipeline identified and quantified the number of CD68+CCR7+ (M1 macrophage phenotype) and 
CD68+CD206+ (M2 macrophage phenotype) cells present within scaffold implantation sites. 
Any cells that co-expressed the CCR7 and CD206 markers were excluded. These values were 
then expressed as a ratio of M1:M2.  
Quantification of CD31 positive blood vessels was done by immunolabeling and 
counting the number of blood vessels per 400x field of view (FOV). Six images of each surgical 
site where quantified by two blinded independent investigators. Only positively labeled cells that 
were associated with a visible lumen were counted. 
2.1.7 Mechanical testing 
Tissue explants were trimmed to dog-bone geometry (midsubstance width 5.7 ± 1.6 mm, length 
20.4 ± 6.6 mm) with exact specimen dimensions dependent on animal and explant size. All 
specimens were subjected to 10 pre-load cycles (25.4 mm/min, 0.1-0.5 N) immediately prior to 
testing to failure (25.4 mm/min). Ultimate tensile stress was calculated from the peak load, 
width, and thickness (2.3 ± 0.5 mm): σ=F/(w*t). Strain at failure was calculated by dividing the 
change in length by the original length: ε=ΔL/Lo. Elastic modulus was taken as the slope of the 
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stress-strain curve in the range of 20-60% of the ultimate tensile stress: E=0.4*σ/(ε60%σ-ε20%σ). 
Five specimens were tested from each control and experimental group with the following 
exceptions: native tissue = 9; SIS-ECM implant from >52 week aged animal (sow) = 4.  
2.1.8 Statistical analysis 
A one-way analysis of variance (ANOVA) was used in conjunction with a Tukey’s post-hoc test 
to compare results between groups. Differences were considered significant at p < 0.05.  
Statistical analysis was completed using SPSS Statistical Analysis Software (IBM, Chicago, IL, 
USA).  
2.2 RESULTS 
2.2.1 Histomorphologic and immunolabeling findings 
All treatment groups elicited a robust cellular infiltrate consisting mostly of mononuclear cells 
after 14 days (Figure 4A). Angiogenesis was also observed in all groups at day 14 and remained 
a feature of the remodeling process throughout the entire study (Figure 5). All of the ECM 
scaffold materials degraded completely based upon morphologic analysis and were replaced with 
host tissue by 180 days. However, there were notable differences in the remodeling responses to 
the different aged ECM materials which are detailed below. 
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 Figure 4: Host cellular response at the surgical site at 14 days post-surgery. The in vivo host response to 
untreated injury, autologous tissue graft, or scaffolds derived from differently aged source ECMs was assessed by 
histologic methods with Masson's Trichrome staining (A) and by the immunolabeling of macrophages (B & C). 
Necrotic islands of skeletal muscle could be identified within the implantation site of the autologous tissue graft 
(arrows). A mononuclear cell infiltrate (morphology depicted in high power inset) was identified throughout the 3, 
12, and 26-week-old scaffolds, while the >52-week-old scaffold was only partially infiltrated (bracket) (A). All 
treatment groups showed the presence of macrophages (CD68; Red). The untreated and autologous implant surgical 
sites displayed a predominant M1 macrophage (CCR7; Orange) phenotype (+, P < 0.001 for both when compared to 
all other treatment groups). The >52 and 26-week-old implant sites were populated by a balanced M1 to M2 
macrophage (CD206; Green) ratio (#, p < 0.004 for both when compared to all other treatment groups). The 3 and 
12-week-old scaffolds displayed a predominant M2 macrophage response (B & C; *,p < 0.004 for both when 
compared to all other treatment groups). Scale bars = 50 μm (inset scale bars = 20 μm), * = scaffold. Error 
bars = standard deviation. 
2.2.1.1 Untreated defect 
Untreated defect sites were characterized by a loose collagenous connective tissue after 14 days. 
A mononuclear cell infiltrate was localized to the defect margins (Figure 4A) Immunolabeling 
studies showed an M1:M2 macrophage ratio of 1.24 ± 0.21 indicating a predominant M1 
macrophage response (Figure 4B,C).  After 180 days untreated defects formed dense collagenous 
tissue consistent with scar tissue (Figure 6). Quantitative analysis of the trichrome staining over 
time showed an increase in the amount of collagenous connective tissue within the defect site 
after 180 days when compared to the 14 day time point (p<0.005) (Figure 8). After 180 days the 
defect site showed no evidence of new skeletal muscle or nerve (Figure 9,Figure 10).  
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Figure 5: Quantitative immunohistochemical analysis of vascularity. CD31 Immunopositive blood vessels were 
counted per 400x field of view (FOV) by two independent investigators. 6 fields per surgical site were examined at 
the interface with underlying host tissue. Untreated, 3, 12, and 26-week-old treated defects showed significant 
vascularity after 14 days that decreased over time. Autologous and >52-week-old treated defects showed a balanced 
level of vascularity throughout the study period. 
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2.2.1.2 Autologous tissue graft 
Treatment of the defect site with autologous tissue elicited a mononuclear infiltrate that was 
localized around the remnants of necrotic skeletal muscle within the autograft after 14 days. 
Similar to untreated defects, immunolabeling studies showed an M1:M2 macrophage ratio of 
1.27 ± 0.24 indicating a predominant M1 macrophage response (Figure 4B,C). Between 28 and 
120 days there was a decreased cellular infiltrate and loss of skeletal muscle within the autograft 
although small islands of necrotic skeletal muscle could still be identified (Figure 7). After 180 
days the autologous tissue graft had remodeled into dense and relatively acellular collagenous 
tissue (Figure 6). The surgical site showed no evidence of new skeletal muscle tissue (Figure 9) 
or signs of innervation (Figure 10). Quantitative analysis of the Masson’s trichrome staining over 
time revealed an increase in the amount of collagenous connective tissue at 180 days when 
compared to the 14 (p<0.01) and 28 (p<0.09) days (Figure 8). 
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Figure 6: Trichrome staining (A) and collagen content quantified (blue staining) using spectral unmixing (B). 
3-week-old and 12-week-old scaffolds showed a constructive remodeling response after 180 days when compared to 
the untreated, autologous, or >52-week-old treated surgical sites as indicated by the formation of site appropriate 
skeletal muscle myofibers within the implant site (A & B). Collagen content showed 3 (p < 0.007) and 12-week-old 
(p < 0.003) scaffolds had significantly less collagenous tissue than the untreated, autologous, or >52-week-old 
treatment groups (B). Means with different symbols are significantly different. Scale bars = 50 μm. Error 
bars = standard deviation 
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2.2.1.3 Neonate aged SIS-ECM scaffold 
The neonate aged SIS-ECM graft showed a mononuclear cell infiltrate throughout the entire 
scaffold at 14 days (Figure 4A). Small remnants of the original ECM implant and a large amount 
of host derived neomatrix were present within the defect site. Immunolabeling studies showed an 
M1:M2 macrophage ratio of 0.67 ± 0.13 indicating a predominant M2 macrophage response 
after 14 days. At 28 days neonate aged SIS-ECM scaffolds showed a decreased cellularity and 
were replaced with host derived matrix (Figure 7). Small Islands of skeletal muscle could be seen 
scattered throughout the defect site after 120 days. At 180 days the implant site contained new 
host tissue that contained organized bundles of new skeletal muscle myofibers surrounded by 
partially organized collagenous connective tissue (Figure 6). In addition, like native tissue and 
feeder treated defects described below, the majority of the muscle fibers within the defect site 
stained positive for fast type II myosin with slow type I myosin fibers dispersed throughout the 
remodeled scaffold placement site (Figure 9). Nerve fibers were present adjacent to the 
myofibers throughout the defect site (Figure 10). Quantitative analysis of the Masson’s trichrome 
stained neonate treated defects showed an increase in collagenous connective tissue between 14 
and 120 (p<.018) (Figure 8). The surgical site further remodeled and became partially replaced 
with skeletal muscle tissue, resulting in a decreased collagen percentage at 180 days when 
compared to the 120 day time point (p<0.03). This collagen percentage at 180 days was not 
significantly different from that at 14 days (Figure 8). 
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Figure 7: Scaffold composition at 14, 28, and 180 days post-surgery. The remodeled tissue was assessed 
histologically with Movats Pentachrome staining. Even at 14 days post-surgery all treatment groups showed no 
observable GAG’s. 3, 12, and 26-week-old scaffolds showed signs of myofiber formation at 180 days post-surgery. 
Scale bars = 50µm. 
 
2.2.1.4 Feeder aged SIS-ECM graft 
The feeder aged SIS-ECM treated defect sites showed a mononuclear cell infiltrate throughout 
the scaffold at 14 days (Figure 4A). In addition at 14 days, small remnants of the original ECM 
implant were present within the defect site. Immunolabeling studies showed an M1:M2 
macrophage ratio of 0.69 ± 0.11 indicating a predominant M2 macrophage response. After 28 
days the SIS-ECM grafts showed decreased cellularity and at 120 days small islands of skeletal 
muscle were present (Figure 7). Feeder aged SIS-ECM scaffolds remodeled in a similar fashion 
to that of the neonate aged SIS-ECM scaffolds. At 180 days the implant site contained new host 
tissue that consisted of organized bundles of skeletal muscle myofibers surrounded by partially 
organized collagenous connective tissue (Figure 6). Similar to native tissue, the majority of the 
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muscle fibers within the defect site stained positive for fast type II myosin with a smaller number 
of widely dispersed slow type I myosin fibers (Figure 9). Nerve fibers were present adjacent to 
the myofibers throughout the defect site (Figure 10). Quantitative analysis of the Masson’s 
trichrome stained feeder treated defect site tissues showed a slight increase in collagenous 
connective tissue between 14 and 120 days (p<.001) (Figure 8). The surgical site further 
remodeled and became partially replaced with skeletal muscle tissue, resulting in a decreased 
collagen percentage at 180 days when compared to the 120 day time point (p<0.004). This 
collagen percentage at 180 days was not significantly different from that at 14 days (Figure 8). 
 
 
 
Figure 8: Connective tissue deposition within each surgical site over time. Quantification of Masson's trichrome, 
in terms of % collagen (blue staining), using spectral unmixing. Untreated defects as well as the autograft and sow 
aged scaffolds induced a steady increase in connective tissue deposition from 14 to 180 days post-surgery. Whereas, 
the feeder and neonate aged scaffolds were associated with a lower collagen presence more similar to that seen in 
native tissue. Means with different symbols are significantly different within each age group. Error bars = standard 
deviation. 
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2.2.1.5 Market aged SIS-ECM graft 
The market aged SIS-ECM treated defect sites showed a mononuclear cell infiltrate throughout 
the scaffold at 14 days (Figure 4A). Original ECM scaffold material could be identified along 
with host derived neomatrix. Immunolabeling studies showed an M1:M2 macrophage ratio of 
0.95 ± 0.24 indicating a balanced macrophage phenotype response (Figure 4B,C). At 28 days the 
surgical site showed a decreased cellularity and increased amount of neomatrix. At 120 days no 
evidence of the original implanted scaffold was observed and small islands of skeletal muscle 
could be identified within the defect site (Figure 7). At 180 days isolated skeletal muscle 
myofibers were dispersed between collagenous connective tissue throughout the defect site 
(Figure 6). These individual myofibers stained positive for fast type II myosin (Figure 9) and 
were adjacent to nerve fibers (Figure 10). Quantitative analysis of the Masson’s trichrome 
staining over time revealed an increase in the amount of collagenous connective tissue at 180 
days when compared to the 14 (p<.001) and 28 (p<.046) day time points (Figure 8). 
 57 
  
Figure 9: Distribution of slow and fast skeletal muscle fibers within the remodeled tissue at 180 days post-
surgery. Tissue sections were double-labeled for anti-myosin slow (type I) skeletal muscle (brown stain) and anti-
myosin fast (type II) skeletal muscle (red stain) to assess myofiber phenotype in the native and remodeled tissue (A). 
The native tissue showed that the slow muscle fibers were uniformly distributed between the fast muscle fibers. The 
remodeled 3 and 12-week-old scaffolds showed a similar distribution. 26-Week-old scaffolds showed predominantly 
fast muscle fibers, whereas the untreated defects, autograft, and >52-week-old scaffolds showed no signs of 
myofiber expression. Quantification of fast vs. slow muscle fibers per field of view (FOV) showed 3-week-old 
scaffolds displayed an increased number of slow muscle fibers when compared to all other surgical sites (B). Scale 
bars = 50 μm. Error bars = standard deviation. 
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2.2.1.6 Sow aged SIS-ECM scaffold 
The sow aged SIS-ECM graft elicited a cellular infiltrate which was localized around the suture 
lines and did not completely penetrate the full thickness of the scaffold at 14 days (Figure 4A). In 
addition at 14 days, much of the original ECM scaffold could be identified along with a small 
amount of host derived neomatrix. Immunolabeling studies showed an M1:M2 macrophage ratio 
of 0.93 ± 0.18 indicating a balanced macrophage phenotype response (Figure 4B,C). After 28 
and 120 days the sow treated defects showed decreased cellularity with remnants of the ECM 
implant (Figure 7). At 180 days the sow treated defect sites contained pockets of cellularity 
surrounded by collagenous connective tissue (Figure 6). No evidence of the originally implanted 
scaffold was observed and there were no signs of new skeletal muscle or innervation (Figure 9, 
Figure 10).Quantitative analysis of the Masson’s trichrome staining over time revealed an 
increase in the amount of collagenous connective tissue at 180 days when compared to the 14 
(p<.001) and 28 (p<.001) day time points (Figure 8).  
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Figure 10: Innervation of remodeled tissue at 180 days post-surgery. Tissue sections were immunolabeled for 
anti-beta-III Tubulin (arrows; brown stain) to identify neurons in the native and remodeled tissue sections. Neurons 
were located adjacent to the myofiber bundles within the native tissue. Similar nerve structures were found around 
myofibers within the remodeled 26, 12, and 3-week-old scaffolds. The remodeled untreated defect site along with 
the >52-week-old scaffold and autograft treated sites showed no signs of innervation. Scale bars = 50 μm. 
2.2.2 Mechanical testing  
Rat abdominal body wall containing remodeled neonate aged SIS-ECM grafts withstood greater 
uniaxial tensile stress compared to all other control and experimental groups as determined by 
ANOVA and Tukey-Kramer post-hoc evaluation (Figure 11A). Strain at failure and modulus did 
not differ significantly for control and experimental groups, including native body wall, body 
wall with a defect site that remained untreated, body wall treated with autologous tissue, or body 
wall treated with SIS-ECM from neonate, feeder, market, or sow aged animals (Figure 11B-C). 
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2.3 DISCUSSION AND CONCLUSIONS 
The present chapter represents a systematic comparison of the in vivo host response to 
xenogeneic biologic scaffold materials that differ by a single variable; specifically, age of the 
animal from which the source tissue was harvested. There are two outcomes of note. First, source 
animal age is an important variable and ECM harvested from neonatal and feeder age pigs 
promotes the formation of greater amounts of site-appropriate skeletal muscle tissue than ECM 
harvested from older pigs. Secondly, the constructive site-appropriate remodeling response is 
associated with a predominant M2 macrophage response.  
 
 
 
Figure 11. Mechanical properties of explanted surgical sites at 180 days post-surgery. Uniaxial tensile testing 
of explants (full thickness of the body wall including underlying and remodeled tissue) was used to characterize 
tissue mechanical properties for comparison to native tissue with respect to strength, distensibility, and stiffness. 
Body wall with remodeled 3-week-old aged SIS-ECM grafts withstood greater stress compared to native body wall 
and all other treatment groups (A). No differences were detected in strain at failure (B) or modulus (C) between 
native body wall and any other treatment group (#, p < 0.05). Error bars = standard deviation. Error bars = standard 
deviation. 
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 It is well known that fetal and neonatal mammals have greater wound healing and 
regenerative potential than adult mammals. The composition of fetal and neonatal ECM is 
distinctly different from that of adults and plays an important role in tissue development (301, 
302). Fetal wounds have increased amounts of glycosaminoglycans (GAGs) such as hyaluronic 
acid and chondroitin sulfate (287, 290) which facilitate cell migration, mitosis, and 
differentiation (291). Compared to ECM in mature mammals, the ECM of fetal tissue is 
composed of more immature collagen containing fewer molecular cross links; a feature which 
promotes rapid degradation and remodeling (303). Therefore it is logical and plausible that 
bioscaffolds composed of ECM derived from fetal or neonatal tissues would induce a more 
robust and constructive tissue remodeling response than ECM derived from adult tissues. The 
results of the present chapter are consistent with this hypothesis. 
The mechanisms by which scaffolds composed of ECM mediate a favorable remodeling 
process are not fully understood but include ECM scaffold degradation with the generation of 
bioactive cryptic peptides (8) release of bound growth factors (16), recruitment of endogenous 
stem and progenitor cells (5, 32), and modulation of the innate immune response (21, 22), among 
others. Of these potential mechanisms, only a component of the innate immune response was 
investigated in the present study; specifically, macrophage phenotype. A previous study 
compared the in vitro structural, mechanical, compositional, and bioactive properties of the same 
differently aged SIS-ECM materials (208). Scaffolds composed of neonatal and feeder aged 
ECM elicited increased progenitor cell chemotaxis and showed greater glycosaminoglycan 
(GAG) content than ECM scaffolds derived from older tissues. The purpose of the present study 
was not to determine cause-effect relationships between these variables, but rather to determine 
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the association of source tissue age within downstream remodeling events in an animal model of 
body wall reconstruction.  
The response of skeletal muscle, which is a prominent natural component of the 
abdominal body wall, to injury is dependent on the temporal participation of different 
macrophage phenotypes (57). These macrophage phenotypes are characterized by distinct 
functional properties, effector molecule production, and surface marker expression (47, 304). 
Macrophage phenotypes range from classically activated (M1) macrophages which are pro-
inflammatory at one end of a spectrum to alternatively activated (M2) macrophages which 
facilitate constructive tissue remodeling and repair at the opposite end of the spectrum (47, 49). 
Following an initial M1 macrophage response which stimulates muscle progenitor cell 
recruitment and mitosis, a subsequent predominant M2 macrophage response promotes the 
differentiation of skeletal muscle precursor cells (57). Inhibition of the M2 phenotype results in a 
severe lack of muscle regeneration and an accentuation of inflammation and necrosis (217). 
Dominant M1 or M2 macrophage populations at the in-situ interface of host tissue with ECM 
scaffolds are associated with either chronic inflammation with fibrotic tissue deposition or site 
appropriate tissue restoration, respectively (305). In the present chapter, scaffolds derived from 
younger animals were associated with a predominant M2 macrophage response after 14 days and 
showed the greatest amount of skeletal muscle at 180 days; a finding consistent with the 
predictive association of the M2 phenotype with favorable remodeling of surgical mesh products 
composed of biologic materials (305). It has previously been shown that surgically implanted 
ECM scaffolds enhance a host M2 macrophage response (22). The specific cause of the robust 
M2 response found within ECM scaffolds manufactured from neonatal or feeder pig tissues is 
unknown.  
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Repair of rat abdominal body wall with SIS-ECM from distinctly different aged animals 
resulted in remodeled tissue with similar mechanical properties to those of native body wall (Fig. 
6). However, SIS-ECM from neonate aged animals remodeled into stronger tissue compared to 
native body wall (Fig. 6A). Based on a previous study (208), it is likely that biologic cues from 
degradation products of neonate SIS-ECM vary from those of degrading SIS-ECM from older 
animals and lead to different downstream remodeling outcomes. It is possible that because the 
neonate scaffolds degraded more rapidly and promoted greater cell migration (208), the skeletal 
muscle tissue that formed within the neonate SIS-ECM treated surgical sites had more time to 
mature, and this in combination with the increased amount of connective tissue, compared to 
native tissue, resulted in stronger tissue. In addition, passive mechanical testing may not have 
been sensitive enough to detect discernable differences in such a small defect site. Furthermore, 
biologic variability between animals may also have masked subtle differences between 
experimental groups. However, mechanical data in this study clearly showed that donor age can 
impact functional outcomes.  
In conclusion, the present chapter examines an important variable that should be 
considered in the design and manufacturing of biologic devices composed of mammalian ECM; 
specifically, the age of the source animal. Biologic scaffold materials derived from younger 
(feeder and neonate) aged animals are associated with a host innate immune response consisting 
predominantly of M2 macrophages and a more robust constructive remodeling response when 
compared to scaffolds prepared from market weight or sow aged pigs. The remaining chapters of 
this dissertation will examine market weight and young (feeder) aged SIS-ECM. 
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2.4 LIMITATIONS AND FUTURE DIRECTIONS 
The present chapter compared xenogeneic biologic scaffold materials differing only in source 
animal age. However, there are limitations that must be noted in the interpretation of the data. 
First, the results represent the findings from a single source tissue of ECM material; specifically 
porcine SIS-ECM. These results cannot necessarily be generalized to ECM prepared from other 
tissue sources such as dermis, urinary bladder, and others. Secondly, ECM materials are prepared 
by decellularization of various tissues, and the decellularization procedures utilized can vary 
significantly. Results of the present study may not apply to materials prepared by other methods 
that affect surface epitopes, biochemical composition, and rate of degradation of various scaffold 
materials. Finally, the association of the M1/M2 macrophage phenotype ratio with constructive 
remodeling does not prove cause-effect.  
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3.0 THE ABILITY OF ECM TO ENHANCE THE POLARIZATION OF 
MACROPHAGES ISOLATED FROM YOUNG AND AGED SUBJECTS AND THE 
EFFECT OF ECM AND POLARIZED MACROPHAGES UPON SKELETAL MUSCLE 
PROGENITOR CELLS 
3.1 BACKGROUND 
Macrophages are recognized as phagocytic and antigen presenting cells responsible for 
propagating the pro-inflammatory response of the mammalian innate immune system (43, 306). 
It is now accepted that macrophages also play a larger role as regulators of tissue homeostasis 
during the host response to disease and tissue injury (45-49). Macrophages, like other myeloid 
cells, are a heterogeneous population of cells capable of assuming different phenotypes. These 
phenotypes are defined by select surface markers, diverse functional properties, and patterns of 
gene expression. Macrophages assume phenotypes that are context dependent and responsive to 
signals from their local microenvironment. Thus, the phenotype of circulating or migratory 
macrophages exists along a spectrum of differentiation (30, 50). Cells on the opposite ends of 
this spectrum, similar to the Th1/Th2 paradigm, are broadly categorized as M1 or M2 
macrophages (307). M1 macrophages are pro-inflammatory or “classically activated” cells 
stimulated by pro-inflammatory factors (e.g., IFNg, LPS). M1 activated macrophages secrete 
toxic reactive oxygen and nitric oxygen intermediates and inﬂammatory cytokines such as IL-1β, 
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IL-6, and TNFα and produce high levels of inducible nitric oxide synthase (iNOS). These cells 
are responsible for microbicidal activity, debris clearance, and the propagation of a pro-
inflammatory and Th1 response. Conversely, “alternatively activated” and constructive M2 
macrophages are stimulated by immunomodulatory and anti-inflammatory factors (e.g., IL-4, IL-
10). M2 activated macrophages express IL-10 and Fizz1; have high levels of scavenger and 
mannose receptors (e.g., CD206); and produce arginase in the place of iNOS, subsequently 
producing ornithine and polyamines. These cells are responsible for propagation of a 
constructive immunomodulatory or Th2 response, matrix deposition, and tissue repair and 
reconstruction (46, 47). Most macrophages likely express a phenotype somewhere between the 
extremes dependent upon microenvironmental cues and temporal factors; however, the factors 
that modulate this macrophage phenotypic profile are only partially understood. 
Adult skeletal muscle tissue retains inherent regenerative potential following minor tissue 
injury (55, 61) that is dependent upon activated skeletal muscle progenitor cells and a temporal 
transition of M1 to M2 macrophages (57). Satellite cell derived myoblasts are the primary stem / 
progenitor cell type responsible for the skeletal muscle regenerative response to injury. However, 
myogenic perivascular stem cells (PVSC) have been shown to occupy the satellite cell niche and 
give rise to myoblasts as well (33, 35, 36). These skeletal muscle progenitor cells become 
activated when effector molecules secreted by M1 macrophages promote their mitogenesis and 
expansion. A transition in macrophage phenotype is necessary for efficient differentiation of 
myoblasts. Specifically, M2 macropahge associated effector molecules promote the fusion, 
myotube formation, and myogenic differentiation of these progenitor cells (57, 215). The factors 
which contribute to the M1 to M2 transition have not yet been identified. 
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Biologic scaffolds derived from mammalian tissues are composed of naturally occurring 
extracellular matrix (ECM) and are referred to as ECM bioscaffolds. ECM bioscaffolds are 
manufactured by tissue decellularization methods which remove pro-inflammatory immunogenic 
cellular material while preserving ECM constiuents such as growth factors and the ECM 
ultrastructure. ECM bioscaffolds have been used, both in pre-clinical animal studies and in 
human clinical applications, to successfully promote constructive tissue remodeling in a variety 
of tissues including skin, bladder, heart, tendon, and skeletal muscle (2, 200-202, 214, 236, 295, 
308). The mechanisms responsible for this constructive remodeling response include the release 
of bioactive degradation products (i.e., cryptic peptides) with the potential for endogenous stem 
and progenitor cell recruitment (5-8, 10, 27, 28, 33) and immunomodulation (21, 22, 29, 30), 
among others. Furthermore, surgically placed ECM bioscaffolds have been associated with a 
predominant M2 macrophage phenotype. The effect of bioactive ECM degradation products 
upon macrophage has not been investigated. 
The objectives of the present chapter were: (1) To determine the effect of ECM 
degradation products upon macrophage phenotype; (2) To determine the effect of young vs. aged 
ECM upon skeletal muscle progenitor cells; and (3) To determine the effect of ECM-treated 
macrophages upon skeletal muscle progenitor cells. 
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3.2 MATERIALS AND METHODS 
3.2.1 Overview of Experimental Design 
Macrophages were derived from bone marrow of C57bl/6 female mice at 6-8 weeks and 20-24 
months of age and treated with pro-inflammatory cytokines to derive M1 macrophages, 
immunomodulatory cytokines to derive M2 macrophages, or degradation products from market 
weight (26 week old) and young (<12 week old) aged small intestinal submucosa (SIS)-ECM. 
Macrophage phenotype was determined by immunolabeling and western blotting for markers of 
M1 and M2 macrophages. In addition, macrophage supernatants and ECMs were investigated as 
potential chemoattractants in a Boyden Chamber cell migration assay to study the recruitment of 
perivascular stem cells (PVSC) and C2C12 skeletal muscle myoblasts (ATCC). To examine the 
effect of macrophages on proliferation of these progenitor cells, mitogenic effects of macrophage 
supernatants and ECMs were evaluated using 5-bromo-2’-deoxyuridine (BrdU) incorporation. 
The influence of macrophages and ECMs on myogenic differentiation was also determined by 
examining the PVSC and myoblast fusion index and sarcomeric myosin-heavy chain expression.  
3.2.2 Preparation of ECM degradation products 
Small intestinal submucosa (SIS)-ECM was prepared from porcine jejunum (298). The SIS-ECM 
was prepared from the market weight (26 week old) and feeder aged (<12 week old) animals as 
described in Chapter 2 of the present dissertation. The resultant SIS-ECMs were lyophilized, 
powdered, and digested at 10mg/ml dry weight with 1 mg/ml pepsin as previously described 
(26). 
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3.2.3 Isolation and culture of murine bone marrow derived macrophages 
Adult, female 6 to 8-week and 20-24 month old C57bl/6 mice obtained from Jackson 
Laboratories (Bar Harbor, ME) were euthanized via cervical dislocation. Using aseptic 
technique, the skin from the top of each hind leg to the foot was removed, the ankle joint was 
disarticulated and the tibia isolated. Similarly, the hip joint was disarticulated for isolation of the 
femur. Excess tissue was removed using forceps and a scalpel blade. Bones were kept on ice and 
rinsed in a sterile dish containing macrophage complete medium consisting of DMEM (Gibco, 
Grand Island, NY), 10% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA), 10% L929 
supernatant, 0.1% beta-mercaptoethanol (Gibco), 100 U/ml penicillin, 100 ug/ml streptomyocin, 
10 mM non-essential amino acids (Gibco), and 10 mM hepes buffer. In a sterile environment, the 
ends of each bone were transected and the marrow cavity flushed with complete medium using a 
30-gauge needle attached to a 10 ml syringe. Harvested cells were spun, filtered, plated, and 
allowed to differentiate into macrophages for 7 days at 37˚C, 5% CO2 with complete media 
changes every 48 hours. 
3.2.4 Polarization and immunolabeling of bone marrow derived macrophages 
After 7 days, resulting naïve macrophages were treated with basal media consisting of DMEM, 
10% FBS, 100 ug/ml streptomyocin, 100 U/ml penicillin and one of the following treatments: (1) 
20 ng/ml IFN-y and 100 ng/ml LPS to derive M1 macrophages, (2) 20 ng/ml IL-4 to derive M2 
macrophages, (3) 200 ug/ml of SIS-ECM degradation products. After 18 hours of incubation at 
37˚C, 5% CO2 cells were washed with sterile PBS, and fixed with 2% paraformaldehyde for 
immunolabeling. The primary antibodies used for immunofluorescent staining were: (1) 
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monoclonal F4/80 (Abcam) at 1:200 dilution for a pan-macrophage marker, (2) polyclonal iNOS 
(Abcam) at 1:100 dilution for an M1 marker, and (3) polyclonal Fizz1 (Peprotech) for an M2 
marker. Cells were incubated in blocking solution consisting of PBS, 0.1% Triton-X , 0.1% 
Tween-20, 4% goat serum, and 2% bovine-serum albumin to prevent non-specific binding for 1 
hour at room temperature. Blocking solution was removed and cells were incubated in primary 
antibodies for 16 hours at 4˚C. After washing in PBS, cells were incubated in fluorophore-
conjugated secondary antibodies (Alexa Fluor donkey anti-rat 488 or donkey anti-rabbit 488, 
Invitrogen) for 1 hour at room temperature. After washing again with PBS, nuclei were 
counterstained with 4’6-diamidino-2-phenylindole (DAPI) prior to imaging. Representative 
images of three 20x fields were taken for each well using a Zeiss Axiovert inverted fluorescence 
microscope. Light exposure times for ECM-treated macrophages were standardized based on 
exposure times set for cytokine-treated internal controls. Images were quantified using a 
CellProfiler pipeline for relative expression of F4/80, iNOS, and Fizz. 
3.2.5 Validation of Macrophage Phenotype with Western Blots 
Western blots were performed on treated macrophage cell lysates. Cell lysates were boiled at 
100˚C for 5 minutes and electrophoresed on 15% acrylamide gels. One-hundred micrograms of 
protein was loaded into each well. Separated proteins were transferred to PVDF membranes 
using a standard wet transfer procedure. Following transfer, membranes were blocked for 18 
hours at 4˚C in TBS-T with 3% milk to prevent non-specific antibody binding. Membranes were 
incubated in the following primary antibodies for 18 hours in 3% milk at 4˚C: (1) polyclonal 
anti-rabbit mannose receptor (Abcam) at 1:714 dilution for an M2 marker, and (2) polyclonal 
anti-rabbit IL-6 (Abcam) at 1:500, and (3) monoclonal anti-mouse B-actin (Santa Cruz) at a 
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dilution of 1:1000 as a loading control. Blots were visualized using a Li-Cor Odyssey western 
blot detection system. Densitometry of protein expression was standardized to the housekeeping 
loading control.  
3.2.6 Progenitor Cell Culture  
Perivascular stem cells isolated from human skeletal muscle as previously described (33) and 
murine C2C12 myoblasts were purchased from ATCC and cultured in DMEM containing 20% 
FBS and 10% FBS, respectively, and 100 ug/ml streptomyocin and 100 U/ml penicillin. Cells 
were grown at 37˚C, 5% CO2 and were assayed for a chemotactic response in a Boyden chamber 
chemotaxis assay when they reached approximately 80% confluence.  
3.2.7 Preparation of Boyden Chamber Test Articles 
For examination of the chemotactic properties associated with market vs. young SIS-ECM 
bioscaffolds, degradation products were generated as described above (26). For examination of 
the chemotactic properties associated with polarized macrophage conditioned media, 
macrophages were polarized or treated with ECM as described above (section 3.2.4). Following 
18 hours of treatment, the media was removed and cells were washed with PBS. Media was then 
replaced with growth factor and ECM free media. Cells were allowed to condition media for 5 
hours at 37˚C, 5% CO2. After 5 hours, supernatants were collected for use as potential 
chemoattractant test articles in a Boyden chamber assay. Following supernatant harvest, cells 
were fixed with 2% paraformaldehyde and stained according to the previously described protocol 
(section 3.2.4) to verify phenotype maintenance following growth-factor withdrawal. 
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3.2.8 Chemotaxis Assay 
Migration of progenitor cells towards ECM degradation products and macrophage-conditioned 
media was investigated using a Boyden chamber assay. C2C12 myoblasts and perivascular stem 
cells were cultured in starvation media (DMEM, 0.5% FBS, 1% penn/strep) for 18 hours prior to 
assay. Cells were then trypsinized, re-suspended in growth factor and serum free DMEM, and 
transferred to a 15 ml conical tube for 1 hour incubation at 37˚C, 5% CO2. Polycarbonate 
chemotaxis membranes with a pore size of 8μm were coated with 0.05 mg/ml collagen type I. 
ECM degradation products (market weight vs. young), macrophage conditioned media (M1, M2, 
SIS-ECM treated), as well as positive (DMEM with 20% FBS) and negative (growth factor and 
serum-free DMEM) controls were added to the lower wells of a Neuro Probe 48-well micro 
chemotaxis chamber. Collagen-coated membranes were placed over the chemoattractants and 
6x105 cells were added to each of the upper wells of the chamber. Cells were allowed to migrate 
across the chamber for 3 hours at 37˚C, 5% CO2. Following the migration period, non-migrating 
cells were scraped from the upper side of the membrane using a rubber scraper and migrated 
cells on the bottom of the membrane were fixed with 95% methanol and stained with DAPI prior 
to imaging. Membranes were imaged using Zeiss Axiovert inverted fluorescence microscope. 
The number of migrated cells was quantified using a custom CellProfiler, image analysis 
software pipeline.  
3.2.9 Mitogenesis Assay 
C2C12 skeletal muscle myoblasts and PVSCs were seeded in normal growth media at 1x103 cells 
per well in a 96 well plate. Media was switched to starvation media (DMEM, 0.5% FBS, 1% 
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penn/strep) for 18 hours. Following the starvation period, cells were treated with ECM 
conditioned media or macrophage supernatants, as well as positive (DMEM with 20% FBS) and 
negative controls (serum free DMEM). Treatments were supplemented with 10 mg/ml 5-bromo-
2’-deoxyuridine (BrdU) for 18 hours for PVSCs and 4 hours for C2C12 skeletal muscle 
myoblasts. Following treatment pulse, cells were fixed with 95% methanol for 10 minutes, and 
washed with PBS. Cells were then treated with 2 N HCl for 30 minutes at 37˚C. Following HCl 
treatment, cells were blocked using the previously described blocking solution for 1 hour at room 
temperature. Following the blocking period, cells were incubated in G3G4 (Anti-BrdU) antibody 
(Developmental Studies Hybridoma Bank) at a dilution of 1:1000 for 16 hours at 4˚C. Following 
primary incubation, cells were washed 3 times with PBS, incubated in Alexa Fluor donkey anti-
mouse 488 at a dilution of 1:300 for 1 hour at room temperature, and counterstained with DAPI 
solution. BrdU incorporation was imaged using a Zeiss Axiovert inverted fluorescence 
microscope and quantified using an ImageJ macro. 
3.2.10 Myogenesis Assay 
Myogenic differentiation potential was determined by examining myotube formation by PVSCs 
and skeletal muscle myoblasts. PVSCs and myoblasts were cultured in normal growth media 
with high serum until they reached approximately 80% confluence. Media was then changed to 
treatment media consisting of (market vs. young) ECM degradation products, macrophage 
supernatants, or high and low serum controls (High serum media retains cells proliferating within 
the cell cycle providing a negative control for differentiation; conversely, low serum induces 
cell-cycle exit and myotube formation providing a positive control) (309). Following 5-7 days, or 
when low serum controls showed myotube formation, cells were fixed for immunolabeling with 
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2% paraformaldehyde, or harvested for western blot analysis. PFA fixed cells were blocked for 1 
hour at room temperature, and incubated in MF20 (anti-sarcomeric myosin) primary antibody 
(Developmental Studies Hybridoma Bank) at a dilution of 1:500 for 16 hours at 4˚C. Following 
primary incubation, cells were washed with PBS and incubated in Alexa Fluor donkey anti-
mouse 488 secondary antibody at a dilution of 1:200 for 1 hour at room temperature and 
counterstained with DAPI. Myotube formation was imaged on an Olympus Axiovert inverted 
fluorescence microscope. 
3.2.11 Statistical analysis 
A one-way analysis of variance (ANOVA) was used in conjunction with a Tukey’s post-hoc test 
to compare results between groups. Differences were considered significant at p < 0.05.  
Statistical analysis was completed using SPSS Statistical Analysis Software (IBM, Chicago, IL, 
USA).  
3.3 RESULTS 
3.3.1 Degradation Products from ECM Bioscaffolds Promote the M2 Macrophage 
Phenotype 
Macrophages were derived from the bone marrow of young (6-8 week) and aged (20-24 months) 
C57bl/6 mice and subsequently exposed to IFNg/LPS, IL-4, or ECM degradation products.  
After 18 hours, degradation products from ECM bioscaffolds promoted M2 macrophage 
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activation similar to IL-4 exposure in macrophages derived from young mice (Figure 12). The 
M2 macrophage phenotype was confirmed using Fizz 1 immunolabeling (Figure 12A), 
quantified using the Cellprofiler image analysis software (Figure 12B) and corroborated using 
CD206 western blotting (Figure 12C). Degradation products from ECM also promoted M2 
macrophage activation in macrophages derived from age-impaired mice (Figure 13). 
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Figure 12: Mammalian ECM promotes the M2 macrophage phenotype. Murine bone-marrow-derived 
macrophages were treated with: 100 ng/ml monocyte colony stimulating factor (MCSF) for derivation of naïve M0 
macrophages, 20 ng/ml IFN-γ & 100 ng/ml LPS for derivation of pro-inflammatory M1 macrophages, 20 ng/ml IL-4 
for immunomodulatory / constructive M2 macrophages, or with 200 μg/ml SIS-ECM degradation products for 18 
hours. Cells were then fixed and immunolabeled for the pan-macrophage marker (F4/80) and for indicators of M1 
(iNOS) and M2 (Fizz1) macrophages (A). Degradation products from SIS-ECM were able to promote the 
constructive M2 macrophage phenotype similar to IL-4 treatment. Quantification of immunolabeling using Cell 
Profiler image analysis software (B). Western blot analysis of the CD206 M2 macrophage marker and the associated 
densitometry normalized to the β-actin housekeeping control (* p < 0.05 for both when compared to all other 
groups). 
 
3.3.2 ECM-Treated and IL-4 induced M2 Macrophages are Chemotactic and 
Myogenic for Skeletal Muscle Progenitor Cells.  
Macrophages were polarized as above, allowed to condition media, and retained their phenotype 
following growth factor and ECM withdrawal (Figure 14). The effect of media conditioned by 
M1, M2, and ECM-treated macrophages upon human PVSCs and C2C12 myoblasts was 
examined (Figure 15). Trends showed that products secreted by IL-4 derived M2 and ECM-
treated macrophages were chemotactic for PVSCs (Figure 15A) and myoblasts (Figure 15B) 
when compared to products secreted by M1 macrophages. Medium conditioned by M1 
macrophages, but not IL-4 induced M2 or ECM treated macrophages was mitogenic for PVSCs 
and (Figure 16). Furthermore, media conditioned by both IL-4 induced M2 and ECM-treated 
macrophages promoted myogenesis of skeletal muscle myoblasts (Figure 17) when compared to 
media conditioned by M1 macrophages. 
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Figure 13: Mammalian ECM promotes the M2 macrophage phenotype in aged macrophages. Murine bone-
marrow-derived macrophages from 20-24 month old mice were treated with the same factors as in Fig 12, but 
required twice the concentrations to achieve polarization. Specifically: 40 ng/ml IFN-γ & 200 ng/ml LPS for 
derivation of pro-inflammatory M1 macrophages, and 40 ng/ml IL-4 for immunomodulatory / constructive M2 
macrophages. 200 μg/ml SIS-ECM degradation products was able to promote the M2 phenotype similar to that of 20 
ng/ml IL-4. Cells were then fixed and immuonlabeled for the pan-macrophage marker (F4/80) and for indicators of 
M1 (iNOS) and M2 (Fizz1) macrophages (A). Quantification of immunolabeling using Cellprofiler image analysis 
software (B).  
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3.3.3 Degradation Products from Market Weight and Young ECM are 
Chemotactic and Myogenic for Skeletal Muscle Progenitor Cells 
The effect of degradation products from market weight (26 week old) and young aged (<12 week 
old) SIS-ECM upon PVSCs and skeletal muscle myoblasts was examined. ECM derived from 
both aged pigs was chemotactic for PVSCs (Figure 18A) and C2C12 myoblasts (Figure 18B) in 
a Boyden Chamber chemotaxis assay when compared to controls. No differences in chemotactic 
activity between market weight vs. young SIS-ECM were identified. Degradation products from 
market weight vs. young SIS-ECM scaffolds were not mitogenic for PVSCs (Figure 19). No 
difference in mitogenic activity between market weight vs. young SIS-ECM was identified. 
Furthermore, degradation products from both market weight and young SIS-ECM were 
myogenic for PVSCs (Figure 20) and C2C12 skeletal muscle myoblasts (Figure 21). Myosin 
heavy chain (MHC) expressing myofibers were more abundant in media conditioned with 
degradation products from both market weight and young SIS-ECM (Figure 20 B,C). 
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Figure 14: Polarized macrophages retain phenotype after growth-factor withdrawal. Murine bone-marrow-
derived macrophages were derived as in Figure 12 & 13. Following polarization or ECM-treatment, the cells were 
washed and replaced with growth factor free media. After 5 hours the supernatants were collected and used in the 
following chemotactic and differentiation assays. Macrophages retained their phenotype at the time of supernatant 
collection.  
3.4 DISCUSSION AND CONCLUSIONS 
The present chapter represents a systematic examination of the effect of mammalian ECM upon 
macrophage phenotype and how ECM-treated macrophages influence the activity of skeletal 
muscle progenitor cells. Furthermore, ECM harvested from different aged animals (market 
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weight [26 weeks old] vs. young [12 week old]) was compared in their ability to affect the same 
skeletal muscle progenitor cells. 
 
 
Figure 15: M2 and ECM-treated macrophages are chemotactic for progenitor cells. Polarized and ECM-treated 
macrophage conditioned media were used as chemoattractants for PVSCs (A) and myoblasts (B).  
 
The results of this chapter showed that degradation products of mammalian ECM were 
directly able to promote the constructive M2 macrophage phenotype, similar to IL-4 exposure, in 
bone marrow derived macrophages from young and old mice. Furthermore, ECM-treated 
macrophage conditioned media was chemotactic for PVSCs and skeletal muscle myoblasts and 
myogenic for skeletal muscle myoblasts. Degradation products from market weight and young 
ECM were chemotactic and myogenic for PVSCs and skeletal muscle myoblasts. Quantitative 
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analysis showed no differences in the chemotactic potential of market weight vs. young ECM. 
However, qualitative analysis suggests a difference in the myogenic potential of these ECMs 
derived from differently aged source material. Specifically, degradation products from young 
SIS-ECM showed an increase in the size of myosin heavy chain positive PVSC derived 
myotubes when compared to market weight SIS-ECM (Figure 20 C). This difference may 
partially contribute to the increased constructive remodeling associated with young SIS-ECM 
from Chapter 2 of the present dissertation. 
 
 
Figure 16: M1 macrophages are mitogenic for progenitor cells. Media conditioned by M1 macrophages induced 
greater BrdU incorporation when compared to media conditioned by M2 or ECM-treated macrophages (*, # p < 
0.05 when compared to each other and all other groups). 
 
Biologic scaffolds composed of mammalian ECM have been associated with a 
predominant M2 macrophage phenotype when surgically placed at sites of tissue injury (21, 22, 
222). The mechanisms behind this M2 response remain largely unknown. The present chapter 
shows that degradation products from SIS-ECM bioscaffold materials directly affect macrophage 
phenotype and promote M2 expression. Furthermore, the study shows that ECM-treated 
macrophages not only express M2 markers (e.g., Fizz1, CD206), they also function as bona fide 
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IL-4 generated M2 macrophages with respect to progenitor cell chemoattraction, proliferation, 
and differentiation. 
 
 
Figure 17: Media conditioned by polarized M2 and ECM-treated macrophages are myogeneic for myoblasts. 
C2C12 myoblasts were cultured in fusion media (low serum), proliferation media (high serum), or proliferation media 
conditioned with supernatants from M1, M2, and SIS-ECM-treated macrophages. Cells were then fixed and 
immunolabeled for sarcomeric myosin heavy chain (MHC) (green).  
It has been shown that a heterogeneous transition of M1 to M2 macrophages is required 
for an efficient host derived regenerative response following skeletal muscle injury (57, 250, 
310). M1 macrophages comprise the predominant cellular response to skeletal muscle injury at 
48 hours post-injury. Conversely, at 3-8 days post-injury, M2 macrophages predominate the host 
cellular response (57). Second only to short-lived neutrophils, classically activated M1 
macrophages represent the next cell-type to invade the wound site, kill pathogens and 
phagocytose myofiber and other necrotic or injured cellular debris, and propagate a type-1 pro-
inflammatory response (215). In addition to these cytotoxic responses, M1 macrophages, through 
effector molecule production, promote skeletal muscle myoblasts to enter the cell cycle and 
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expand (216, 311). During the resolution of inflammation at the injury site, there is a phenotypic 
switch of macrophages towards the M2 or constructive phenotype. M2 macrophages, through 
effector molecule production, promote immunomodulation and the myogenic differentiation of 
the expanded skeletal muscle myoblasts (217, 312). The present chapter confirms these 
phenomena, showing that M1 macrophage conditioned media promote the proliferation of 
skeletal muscle progenitors, while M2 macrophage conditioned media promotes chemotaxis and 
myogenesis of skeletal muscle progenitor cells. Moreover, the chapter shows that ECM-treated 
M2 macrophages promote chemotaxis myogenesis similar to IL-4 activation. 
 
 
Figure 18: Degradation Products from ECM are chemotactic for progenitor cells. Skeletal muscle progenitor 
cells were seeded at 30,000 cells/well in a chemotaxis chamber and allowed to migrate for 3 hours at 37oC. Migrated 
cells were fixed, stained with Dapi nuclear stain, and imaged using a Zeiss Axiovert fluorescence microscope. 
Images were quantified using Cell Profiler image analysis software. Degradation products of SIS-ECM, at a 
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concentration of 200 ug/ml, were chemotactic for Perivascular stem cells (PVSCs) (A) and C2C12 skeletal muscle 
myoblasts (B) (*p < 0.05 when compared to all other groups). 
3.5 LIMITATIONS AND FUTURE DIRECTIONS 
The present chapter showed that ECM promotes the M2 macrophage phenotype, and compared 
market weight vs. young source aged ECM. However, there are limitations that must be noted in 
the interpretation of the data. First, although the study shows that degradation products directly 
promote differentiation of the M2 macrophage phenotype, it remains unknown which factor(s) 
are responsible for this effect. Similarly, it is unknown which pathway is activated within naïve 
macrophages, following ECM exposure, driving M2 gene expression. The in vitro studies from 
this chapter were completed using the mouse C2C12 skeletal muscle myoblast cell line and 
corroborated using human PVSC primary cells. Although no direct comparison between cell 
types is made, this species difference must be acknowledged. The mitogenic effects of ECM 
degradation products and polarized macrophages was only examined in PVSCs. Future studies 
will test the mitogenic effects of these treatment groups against myoblasts. PVSC myogenesis 
was only tested in response to market weight vs. young ECM, studies are ongoing examining the 
myogenic effects of polarized and ECM-treated macrophages upon this cell-type. Finally, 
myoblast fusion and myotube formation was only qualitatively analyzed, future studies will 
provide quantitative analysis of this phenomenon. 
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Figure 19: Degradation Products from ECM are not mitogenic for PVSCs. Media conditioned with market 
weight SIS-ECM (SIS) and young SIS-ECM (y SIS) did not induce BrdU incorporation at 50, 100, or 200 ug/ml  
concentrations (# p < 0.05 when compared to all other groups). 
 
 
 
Figure 20: Degradation products from ECM are myogeneic for PVSCs. PVSCs were cultured in fusion media 
(low serum), proliferation media (high serum), or proliferation media conditioned with 100 ug/ml market weight 
SIS-ECM (SIS) and young SIS-ECM (SIS-Y). Cells were then fixed and immunolabeled for sarcomeric myosin 
heavy chain (MHC) (green) (A). Images were quantified by counting the number of fused MHC cells / region of 
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interest (ROI) (B), and the number of nuclei in MHC+ cells / ROI (C) (* p < 0.05 when compared to all other 
groups). n=3. 
 
 
 
Figure 21: Degradation products from ECM are myogeneic for C2C12 skeletal muscle myoblasts. Myoblasts 
were cultured in fusion media (low serum), proliferation media (high serum), or proliferation media conditioned 
with 100 ug/ml market weight SIS-ECM (SIS) and young SIS-ECM (Young SIS). Cells were then fixed and 
immunolabeled for sarcomeric myosin heavy chain (green). 
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4.0 ECM MEDIATED CONSTRUCTIVE REMODELING IN A MOUSE MODEL OF 
VOLUMETRIC MUSCLE LOSS 
4.1 BACKGROUND 
Adult skeletal muscle has robust inherent ability to regenerate in response to injury (55, 61, 62). 
Skeletal muscle damage associated with crush injury or blunt trauma is typically associated with 
a host response that relies in large part upon the presence and activation of a myogenic stem cell 
population called satellite cells. Satellite cells possess the ability to exit quiescence, divide, 
migrate and differentiate into myoblasts and then fuse into multinucleate muscle fibers (313). 
The regenerative process has been described as occurring in 3 stages: a proliferative phase, the 
early differentiation stage, and the terminal differentiation stage. Each stage is regulated in part 
by the temporal expression of well-recognized muscle transcription factors of the basic helix-
loop-helix family (314).  However, this regenerative response is critically dependent upon the 
type and severity of muscle insult (313). When skeletal muscle injury is more severe and cannot 
be compensated via inherent regenerative mechanisms, the resulting irrecoverable loss of tissue 
is referred to as volumetric muscle loss (VML) (74).  
Common causes of VML include military battlefield injuries (315-317), civilian 
traumatic accidents, tumor ablation, or degenerative disease, and are associated with cosmetic 
and functional impairment. In the military setting, muscle trauma now accounts for between 50% 
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and 70% of total war injuries with 80% of the surgical amputations performed on military 
casualties directly related to this missing tissue (318, 319). Therapeutic options for VML are 
very limited and include autologous tissue transfer, muscle transposition, or amputation with the 
implementation of prosthetic devices. These procedures however, have yielded minimal success 
(67-69) and are associated with extensive donor site morbidity (320, 321). The lack of a reliable 
and easily reproducible animal model of VML has delayed the development of more effective 
treatment strategies. 
Surgically placed biologic scaffolds composed of naturally occurring extracellular matrix 
(ECM) have been used to promote the site appropriate constructive remodeling of soft tissue 
defects within the abdominal wall musculature (21, 202, 203, 206), musculotendinous junction 
(200), esophagus (194, 278) and heart (322). ECM mediated constructive remodeling has been 
associated with enhanced functional myogenesis (202), innervation (205) and vascularization 
(202, 203, 206) within the remodeling scaffold. Therefore, scaffolds composed of ECM may 
provide a viable therapeutic approach for the clinical treatment of VML. 
In the present study, a preclinical rodent model of VML that involved a unilateral 
excisional defect of the mouse quadriceps muscle was developed and evaluated. After 56 days, 
histologic examination revealed the defect to be of critical size and healed with dense 
collagenous scar tissue. Using this model, a bioscaffold-based regenerative medicine approach to 
VML treatment and the role of polarized macrophages and multipotent perivascular stem cells 
(PVSC)s in the remodeling process was evaluated. 
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4.2 MATERIALS AND METHODS 
4.2.1 Overview of Experimental Design 
Approval was obtained from the University of Pittsburgh Institutional Animal Care and Use 
Committee. Thirty-two female C57BL/6 mice were randomly assigned into either treated or 
untreated experimental groups.  Both groups were subjected to a muscle defect consisting of 
unilateral resection of the tensor fascia latae quadriceps muscle. The defects within the treated 
group were filled with a biologic scaffold composed of porcine derived small intestinal 
submucosa (SIS)-ECM. Non-resorbable marker sutures were placed at the corners of the defect 
in both groups and were used to identify the defect margins. The time points for evaluation were 
7, 14, 28, and 56 days (n=4 per time point / group). Microscopic analysis included 
histochemistry and immunolabeling to examine macrophage phenotype, progenitor cell activity, 
skeletal muscle regeneration, vascularization, and innervation. 
4.2.2 Scaffold Preparation 
The SIS-ECM material was prepared by decellularization of porcine jejunum using a 
combination of mechanical and chemical methods as previously described (323). This material 
was then lyophilized and milled to produce particulate SIS with dimensions of 850 mm2, and 250 
mm2. This particulate SIS was combined in a ratio of 2:1, respectively, and vacuum pressed to 
form a “powder pillow” construct 25x12.5x3mm. This construct was cut into smaller pillows 
4x4x3mm weighing approximately 27.6 ± 04.5 mg to be used as implants.  Lyophilized SIS 
sheets (1 cm2) were used to secure the pillows within the defect. 
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 4.2.3 Surgical Procedure 
Female C57BL/6 mice, age 6-8 weeks, were purchased from Jackson Laboratories (Bar Harbor, 
ME). Mice were anesthetized and maintained at a surgical plane of anesthesia with 1.5-2.5% 
isoflurane in oxygen and positioned in ventral recumbency. The surgical site was prepared in 
sterile fashion using a commercially available hair remover and 70% isopropyl alcohol followed 
by the placement of sterile drapes. A unilateral longitudinal incision measuring approximately 
1.5 cm in length was made in the epidermis, dermis, and fascia to expose the underlying 
quadriceps compartment (Figure 12A). Following resection of a 4mm x 3mm full thickness 
segment of the tensor fasciae latae muscle along with a partial resection of the underlying rectus 
femoris, marker sutures (7-0 prolene, Ethicon Inc.) were placed along the deep corners of the 
defect and anchored through the rectus femoris muscle (Figure 12B). Sutures were placed to 
clearly identify the injury and / or implantation site at the time of tissue harvest. In the untreated 
group the most superficial edge of each defect was also marked by a simple interrupted suture. A 
minimal amount of suture material was placed only at the defect corners to avoid eliciting a host 
response to the suture that would obscure the host response to the injury alone.  Defects in the 
treated group were filled with SIS-ECM powder pillows (Figure 12C) and covered by a cubic 
centimeter of SIS-ECM sheet. The sheet was then sutured to the top edges of the defect in an 
interrupted fashion similar to the control (Figure 12D). The entire sheet-pillow implant was 
hydrated using normal saline prior to dermal closure with 7-0 prolene in a continuous pattern. 
The wound was covered in betadine ointment after closure and assessed for signs of infection for 
2 days post-surgery. Each mouse received Buprenex (buprenorphine hydrochloride, 0.25 mg/kg) 
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for analgesia, and Baytril (enrofloxacin, 20mg) an antibiotic, for three days post-operatively. All 
animals survived the surgical procedure and their predetermined study period without 
complications. 
 
 
Figure 22: Induction of VML injury. The exposed quadriceps muscle compartment after skin incision and blunt 
dissection of the surrounding fascia (A). Volumetric defect consisting of a 4×3 mm full-thickness resection of the 
tensor fasciae latae quadriceps muscle (B). Treated defect filled with a size-matched piece of vacuum-pressed SIS-
ECM (C). Single-layer SIS-ECM sheet overlay sutured to adjacent native muscle before dermal closure (D). VML, 
volumetric muscle loss; SIS, small intestinal submucosa; ECM, extracellular matrix. 
 
4.2.4 Specimen Harvest and Histology 
Animals were sacrificed at 7, 14, 28, and 56 days. Each mouse was euthanized with 5% 
isoflurane in oxygen followed by an intracardiac injection of potassium chloride to induce 
cardiac arrest. The defect site and associated proximal and distal segment of the quadriceps 
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muscles were isolated and surgically removed. The isolated tissue was either (1) flash frozen in 
liquid nitrogen cooled 2-methyl butane or (2) fixed in 10% neutral buffered formalin (NBF). 
Frozen tissues were embedded in OCT compound and cryosectioned into 8-µm thick sagittal 
sections. NBF fixed tissue was embedded in paraffin and cut into 5-µm thick sagittal sections. 
All tissue sections were mounted onto glass slides for histologic staining (i.e: Masson’s 
Trichrome) or for immunolabeling analysis. 
4.2.5 Immunolabeling Studies 
Frozen tissue sections were fixed in ice cold 50:50 methanol:acetone for 5 mins at room 
temperature and washed in PBS. Tissue sections were blocked in blocking buffer (1% (w/v) 
bovine serum albumin / 2% (v/v) normal horse serum / 0.05% (v/v) Tween-20 / 0.05% (v/v) 
Triton X-100 in PBS) for 1 hour to reduce non-specific antibody binding. Tissue sections were 
then incubated in primary antibodies diluted in blocking buffer at 4 OC for 16 hours. The primary 
antibodies used for the immunolabeling studies were: (1) rabbit polyclonal CD31 (Abcam, 
Cambridge, MA) or von-Willebrand factor (vWF) on NBF fixed tissues at 1:200 dilution for 
identiﬁcation of endothelial cells; (2) rabbit polyclonal Gap-43 (Abcam, Cambridge, MA) on 
NBF fixed tissues at 1:200 for identification of neurons; (3) monoclonal anti-desmin (Abcam, 
Cambridge, MA) on frozen fixed tissues at 1:200 dilution for identiﬁcation of muscle cells; (4) 
monoclonal anti-iNOS and Fizz1 on NBF fixed tissues for identification of M1 and M2 polarized 
macrophages respectively; (5) monoclonal anti-CD146 for identification of perivascular stem 
cells (PVSC). After washing in PBS, tissue sections were incubated in fluorophore conjugated 
secondary antibodies (Alexa Fluor® donkey anti-mouse or donkey anti-rabbit 488 or 594, 
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Invitrogen). After washing again with PBS, nuclei were couterstained with DAPI and slides were 
coated with anti-fade mounting media (Dako). 
 NBF fixed tissues were deparafﬁnized with xylene and rehydrated through a graded 
ethanol series. Heat-mediated antigen retrieval was performed with 0.1 mM EDTA buffer at 95-
100 OC for 25 min. After cooling for 15 min, enzyme-mediated antigen retrieval was performed 
with 0.1% (v/v) trypsin / 0.1% (w/v) calcium chloride digestion at 37 OC for 10 min. After 
washing in PBS tissue sections were blocked in blocking buffer for 1 hour and incubated in 
primary antibodies at 4 OC for 16 hours. After additional PBS washing tissue sections were 
incubated in secondary antibodies for 1 hour at room temperature, followed by DAPI nuclear 
stain before coverslipping. All tissue sections were imaged using a Zeiss Axio Observer Z1 or 
Nikon E600 microscope with Nuance multispectral imaging system (CRI Inc, Cambridge MA) 
with appropriate brightfield and fluorescent filter sets. Quantification of CD31 positive blood 
vessels was done by immunolabeling and counting the number of blood vessels per 400x field of 
view (FOV). Three images of each surgical site where quantified by two blinded independent 
investigators. Only positively labeled cells that were associated with a visible lumen were 
counted. 
4.2.6 Statistical Analysis 
An independent Student’s t-test was used to determine the differences in vascularity between 
SIS-ECM and no treatment at 7, 14, 28, and 56 days post-injury.  All statistical analysis used 
SPSS Statistical Analysis Software (SPSS, IBM, Chicago, IL, USA). 
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4.3 RESULTS 
4.3.1 Surgical Procedures 
All mice recovered from the surgical procedure without complications. The behavior and 
appetite of all subjects were unchanged following the procedure. No macroscopic abnormalities 
were noted at the time of removal of skin sutures (10-14 days after the procedure) or throughout 
the duration of the study.  
 
 
Figure 23: VML injury is of critical size. Histological analysis of uninjured (A) and injured (B) muscle at 56 days 
post-surgery. After 56 days low-power magnification (left panels) reveals an obvious volumetric defect (dotted line). 
Higher magnification (right panels) shows the defect partially remodeled with a collagenous connective tissue 
consistent with scar formation ({) and some adipose (*). No signs of new skeletal muscle formation are seen in 
untreated injured muscle. The black boxes on the left represent the area of the high-power images on the right (scale 
bar=1 mm). 
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4.3.2 Macroscopic and Microscopic Findings 
4.3.2.1 Control Group  
Mice were allowed to heal for 56 days following surgical excision of a 4mm x 3mm full 
thickness resection of the tensor fasciae latae and rectus femoris muscles in mouse quadriceps 
muscle. After 56 days post-surgery the volumetric defect remained and was easily identifiable by 
histologic methods (Figure 13B, left panel, dotted line). The defect only experienced a mild 
flattening and associated deposition of a thin layer of disorganized, collagenous scar tissue 
(Figure 13B, Right Panel). The persistence of a volumetric defect and deposition of collagenous 
connective tissue was consistent with a critical size defect, irrecoverable by the inherent 
endogenous regenerative potential of skeletal muscle. These results show that the VML injury 
model is of critical size and does not spontaneously heal. 
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Figure 24: Defect site at 7 days post-surgery. Low magnification (left panels) shows the defect site (dotted lines). 
Untreated defects (A) show a VML injury characterized by necrotic skeletal muscles (arrows), while treated 
defects (B) are filled with the SIS-ECM scaffold. High magnification (right panels) shows a robust mononuclear cell 
infiltrate in both untreated and treated defects. The black boxes on the left represent the area of the high 
magnification images on the right (scale bar=1 mm).  
 
The host response to untreated VML defects showed necrosis of skeletal muscle 
immediately surrounding the defect margins after 7 days (Figure 14A, arrows). Neutrophils and 
mononuclear cells were present within the wound site at day 7. New blood vessels were present 
at day 7 and persisted through 28 days post-surgery (Figure 19A & C). CD146+ Multipotent 
perivascular stem cells (PVSC) remained in their normal anatomic location, around vWF+ 
vasculature after 7 days (Figure 17). Gap-43+ nerve fibers were also observed around the defect 
margins at the interface with native muscle from days 7-28 post-surgery but did not extend into 
the defect site itself (Figure 20A). By day 14, the defect site became partially filled with 
granulation tissue and the cells populating the defect site were predominantly mononuclear in 
morphology (Figure 15A). This mononuclear cell infiltrate was characterized by the predominant 
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expression of the pro-inflammatory M1 marker iNOS (Figure 16). After 14 days, CD146+ 
PVSCs remained in their normal anatomic location. By day 28 the cell population showed a 
marked decrease in number and host derived neomatrix could be identified along the margins of 
the defect site (Figure 18A). After 56 days the untreated defects were characterized by dense 
partially organized connective tissue consistent with scar tissue formation within the injury site 
(Figure 13B,Right Panel). 
 
 
Figure 25: Defect site at 14 days post-surgery. Low magnification (left panels) shows the defect site (dotted lines). 
Untreated defects are filling with granulation tissue, while the ECM scaffold is becoming infiltrated with cells. The 
black boxes on the left represent the area of the high magnification images on the right. (#, host derived neomatrix; 
*, scaffold) (scale bar=1 mm). 
 
4.3.2.2 SIS-ECM Treated Group  
The host response to VML defects treated with an SIS-ECM scaffold was characterized by a 
dense infiltration of both neutrophils and mononuclear cells that surrounded the defect site and 
populated the outer edges of the scaffold at 7 days post-surgery, similar to untreated control 
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groups (Figure 14B). CD146+ PVSCs were found in their normal anatomic location (Figure 17) 
Angiogenesis was prominent at day 7 and remained a feature of the ECM treated defect 
throughout the 56 day study period (Figure 19B) Nerve fibers were present within the 
remodeling scaffold after 7 days and for the duration of the study period (Figure 20B). After 14 
days a uniformly distributed population of mononuclear cells populated the majority of the ECM 
scaffold (Figure 15B). Unlike untreated defects, this cell infiltrate was characterized as 
predominantly M2 macropahges by the expression of Fizz1 (Figure 16). In further contrast to the 
untreated group, CD146+ PVSCs were identified outside their normal anatomic location (Figure 
17), suggesting that they participate in the remodeling of the ECM scaffold. Host derived 
neomatrix was intermingled with remnants of the ECM scaffold within the defect site. After 28 
days, the majority of the ECM implant was cellularized, with the exception of a few areas within 
the center of the scaffold (Figure 18A). Abundant neomatrix along with native skeletal muscle 
ingrowth could be identified along the scaffold margins. At 56 days post-surgery, the ECM 
scaffold was almost completely cellularized (Figure 21A), showed islands of desmin+ cells along 
the interface with the underlying native muscle (Figure 21B, Left Panel) and was populated by 
islands of desmin+ striated skeletal muscle cells throughout (Figure 21B, Right Panel). 
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Figure 26: Macrophage Phenotype. After 14 days, untreated VML defects are associated with a predominant M1 
macrophage phenotype (iNOS staining), while ECM scaffold treated VML defects are associated predominantly 
with M2 constructive macrophages (Fizz1 staining). 
4.4 DISCUSSION AND CONCLUSIONS 
The present chapter describes a murine model of volumetric skeletal muscle injury that does not 
spontaneously heal. In addition, the findings of the present study showed that implantation of a 
biologic scaffold composed of extracellular matrix at the site of injury alters the default wound 
healing response from scar tissue deposition toward constructive remodeling, including the 
presence of new innervated and vascularized skeletal muscle.  
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Figure 27. Perivascular Stem Cell Activation. After 14 days, without ECM intervention, CD146+ PVSCs remain 
in their normal anatomic location (B, top panels). In contrast, SIS-ECM treated defects are populated with vessel-
unassociated PVSCs outside their normal anatomic location (B, bottom panels, arrows), suggesting that they 
participate in the remodeling of the ECM scaffold. 
 
Skeletal muscle has a robust capacity for regeneration following injury. The accepted 
paradigm of skeletal muscle regeneration is that quiescent satellite cells located beneath the 
basement membrane become activated and differentiate into new myotubes (60, 324-328). 
However, although debated, it is increasingly being recognized that there are additional 
progenitor cell populations that have the ability to form new muscle tissue (121, 329-332). 
Common rodent models used to experimentally induce skeletal muscle injury include cardiotoxin 
injection (333), freezing (257, 334), and eccentric contraction-induced injury (335, 336) among 
others. Although these skeletal muscle injury models induce a significant amount of localized 
injury acutely, the tissue is typically able to be restored to native structure and function by the 
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inherent regenerative capacity of skeletal muscle. Therefore, these canonical skeletal muscle 
injury models would be ineffective in studying potential VML therapies because of this 
spontaneous recovery. The present study describes a critical size volumetric muscle defect within 
an extremity, specifically within the quadriceps muscle compartment. 
 
 
 
Figure 28. Defect site at 28 days post-surgery. Low magnification (left panels) shows the defect site (dotted lines). 
High magnification (right panels) shows predominantly spindle-shaped cells populating the untreated defect site (A), 
while treated defects are comprised of cells with varying morphologies (B). The black boxes on the left represent the 
area of the high-magnification images on the right (scale bar=1 mm). 
 
There are very limited therapeutic options for massive and overt loss of skeletal muscle 
tissue subsequent to trauma. Autologous muscle grafts or muscle transposition represent possible 
salvage procedures for restoration of absent muscle tissue but these approaches have limited 
success and are plagued by the associated morbidity at the donor site. Cell based therapies are in 
their infancy and to date have been focused largely upon hereditary muscle disease such as 
Duchenne Muscular Dystrophy. There is an unequivocal need for regenerative medicine 
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strategies that can enhance the innate regenerative ability of skeletal muscle following traumatic 
injury and/or induce de novo formation of functional muscle tissue due to congenital absence of 
such tissue. Development of a therapy that avoids the collection, isolation and/or expansion and 
purification of autologous stem cells with subsequent re-introduction to the patient would almost 
certainly reduce the regulatory hurdles for clinical translation, reduce the cost of treatment, and 
avoid the risks associated with cell-based approaches.  
 
 
 
Figure 29. Vascularity of treated versus untreated VML defects. CD31 staining (green) of endothelial cells at 7, 
14, 28, and 56 days after VML in untreated defects (A) or defects treated with an SIS-ECM scaffold (B). CD31 
immunopositive blood vessels were counted per 400× field of view (C). Three fields per surgical site were examined 
at the interface with underlying host tissue (*p<0.01) (scale bar=1 mm). (Error bars=standard deviation). 
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 Surgically placed biologic scaffolds composed of naturally occurring ECM have been 
used previously in pre-clinical studies to promote constructive remodeling of soft tissue defects 
(200, 337). Although such studies have not evaluated the ability of ECM scaffolds to promote 
constructive remodeling of volumetric muscle injuries, implantation of an ECM scaffold at a site 
of muscular injury resulted in deposition of site appropriate, functional muscle within 6 months 
post-implantation (202). The mechanisms underlying this process are not well understood, 
however rapid angiogenesis, degradation of the ECM scaffold, recruitment of differentiated and 
progenitor cells, and local modulation of the immune response are all logical and plausible 
factors that contribute to ECM-mediated remodeling of muscular tissue (205, 294, 337, 338). 
   
 
Figure 30. Evidence of innervation within treated versus untreated VML defects. Representative images of 
Gap-43+ (green) neurons at 7, 14, 28, and 56 days after VML in untreated defects (A) or defects treated with an SIS-
ECM scaffold (B) (scale bar=1 mm). 
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Previous studies have shown that cells which accumulate at a site of ECM implantation 
include macrophages (21, 22), multipotential stem/progenitor cells (5, 7), endothelial cells (186, 
339), nerves (205), and muscle cells (202). The temporal appearance of these cell phenotypes is 
likely dependent upon anatomic site (294), microenvironmental niche factors (160), and 
epigenetic factors such as mechanical forces (295). Degradation products of ECM scaffolds have 
been shown to include chemotactic factors for myogenic progenitor cells (5, 11, 33). Thus it is 
possible that a subset of the dense mononuclear cells includes progenitor cells with myogenic 
potential. Future studies will further investigate the spatial and temporal pattern of accumulation 
of various myogenic progenitor cells following implantation of an ECM scaffold at a site of 
volumetric muscular injury. 
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Figure 31. Site-appropriate remodeling by ECM scaffolds. Defect sites treated with SIS-ECM (dotted line) 
maintain robust high cellularity after 56 days (A). Immunolabeling shows desmin+ cells (green staining) populating 
the area of ECM implantation along the interface of the underlying native muscle [(B), left panel]. Desmin+-striated 
skeletal muscle cells were also observed throughout the SIS-ECM scaffold [(B), right panel]. The black box on the 
left represents the area of the high magnification image on the right.  
 
Site appropriate and constructive remodeling following a traumatic VML injury would 
intuitively be associated with a robust cellular response including prolonged angiogenesis and 
neurogenesis. The present study shows that following injury, ECM treated and untreated VML 
defects are both characterized by a robust mononuclear response consisting of many different 
cell types including endothelial and nerve cells at 7 – 28 days post-injury. However, these treated 
vs. untreated injury responses are dissimilar at 56 days post-injury. After 56 days the ECM 
treated defects continue to show angiogenesis, the presence of nerves, and a diffuse cellular 
infiltrate that includes desmin+ striated skeletal muscle cells.  In contrast, at 56 days post-injury, 
untreated defects show a response consistent with default wound healing and scar formation 
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including a decreased cellular infiltrate and no signs of angiogenesis, innervation, or skeletal 
muscle. This murine model represents a useful tool for studying potential VML therapies. 
In conclusion, the present chapter describes a model of volumetric muscle injury that 
does not spontaneously heal. The placement of an ECM scaffold at the site of injury results in a 
significant deviation from the default response of scar tissue deposition toward a more 
constructive remodeling outcome including the formation of desmin+ islands of muscle within 
the ECM construct. Although the mechanisms underlying this process are not yet fully 
understood, the development of a murine model allows for a more sophisticated and in-depth 
investigation of potential mechanisms by which ECM scaffolds promote constructive 
remodeling. 
4.5 LIMITATIONS AND FUTURE DIRECTIONS 
The present chapter developed a mouse model of VML and evaluated a bio-scaffold based 
regenerative medicine approach for site-specific tissue replacement. However, there are 
limitations that must be noted in the interpretation of the data. First, the results represent 
remodeling outcomes up to 56 days post-injury. Although desmin+ striated skeletal muscle cells 
were populating the scaffold implantation site, future studies of longer duration will prove if 
these cells have the capability to fuse and span the length of the defect. Secondly, the present 
study uses iNOS and Fizz immunolabeling to identify and distinguish between M1 and M2 
macrophages respectively. Because macrophage phenotypes evolve along a spectrum of 
differentiation, more than a single M1 vs. M2 marker is desirable for effective identification of 
phenotype. Therefore, although iNOS and Fizz are strong indicators of M1 vs. M2 macrophages, 
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future studies will corroborate these findings with other markers of macrophage as well as pan 
macrophages. The present study is lacking functional testing. Future studies examining the extent 
of functional recovery after a longer study period are warranted and in progress. Finally, the 
study shows perivascular stem cells (PVSC) found outside their normal perivascular niche and 
participating in the remodeling of the ECM scaffold. Although this phenomenon correlates with 
downstream islands of desmin+ skeletal muscle cells, future studies employing transgenic 
technologies and lineage tracing are necessary to determine if the PVSCs give rise to the de novo 
skeletal muscle cells. 
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5.0 CLINICAL TRANSLATION OF EXTRACELLULAR MATRIX BIOSCAFFOLDS 
5.1 BACKGROUND 
Skeletal muscle accounts for more than 40% of the body’s mass (54, 340) and, unlike most other 
tissues in the adult mammal, possesses the inherent ability to regenerate following injury (53, 55, 
341-344).  However, the regenerative response fails when a large volume of muscle is lost as a 
result of trauma; i.e., volumetric muscle loss (VML) (74),  and the default outcome is scar tissue 
formation (10-14). Treatment options for VML are limited and include scar tissue debridement 
and/or muscle transposition, both of which are typically associated with morbidity and 
unfavorable outcomes (67, 320, 321, 345, 346). 
Skeletal muscle regeneration relies in large part upon the activation, proliferation, migration 
and differentiation of the canonical muscle stem cell, termed the satellite cell, within a conducive 
and permissive microenvironmental niche (55, 60-62, 313, 347). Other stem/progenitor cell 
populations, such as perivascular stem cells (PVSC; CD146+, NG2+) have been shown to play 
important roles in skeletal muscle regeneration (33, 100, 348-351).   The response of skeletal 
muscle to injury is critically dependent upon the innate immune response; particularly the 
recruitment, accumulation, activation, and temporal polarization of macrophages (i.e., M1/ M2 
phenotype) (57, 352).  Finally, the extracellular matrix (ECM) of all tissues largely defines the 
microenvironmental niche and modulates the migration, behavior, and phenotype of resident 
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cells during development, homeostasis, and in response to injury (161, 353-355). While most 
strategies to address the loss of muscle mass have been cell-centric, the present study describes 
an acellular approach that is based upon use of an ECM biologic scaffold to provide a supportive 
microenvironmental niche that influences endogenous cell behavior at the site of interest.  
Surgical placement of acellular biologic scaffold materials composed of mammalian ECM 
promotes a constructive, functional skeletal muscle response following experimentally-induced 
skeletal muscle injury in small (21, 179, 181, 182, 202, 210, 356-358) and large (200, 204) 
animal models. There is also an anecdotal report of the use of an ECM bioscaffold in a human 
patient following extremity trauma with VML (201). This ECM-mediated response occurs by 
mechanisms thought to include the recruitment of stem/progenitor cells via the formation of 
chemotactic cryptic peptides (5, 7, 8, 10, 186, 359) and modulation of macrophage phenotype 
(21, 22, 24, 29, 222, 338). 
Herein, we report the use of a recently described rodent model of VML to evaluate the effect 
of an ECM biologic scaffold upon the healing response (357).  Results show the presence of 
PVSC both surrounding neovasculature and spatially distinct from vascular structures during the 
process of ECM scaffold remodeling, and the associated de novo formation of skeletal muscle 
fibers. In a parallel human clinical study, five patients suffering from extremity VML were 
treated with an ECM biologic scaffold and showed not only a similar presence and distribution 
of PVSCs with associated de novo formation of skeletal muscle as observed in the rodent model, 
but also a functional improvement in three of the five patients. 
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5.2 MATERIALS AND METHODS 
5.2.1 Mouse Model of Volumetric Muscle Loss 
Experimental design, scaffold preparation, surgical procedure, and tissue harvest were performed 
as previously described (357). Briefly, approval was obtained from the University of Pittsburgh 
Institutional Animal Care and Use Committee. Twenty-four female C57BL/6 mice were 
randomly assigned into either treated or untreated experimental groups. Both groups were 
subjected to a muscle defect consisting of unilateral resection of the tensor fascia latae 
quadriceps muscle. The VML defect accounts for a loss of approximately 90% of the fascia latae 
and 60% of the rectus femoris. In total, the defect represents a volumetric loss of approximately 
75% of the quadriceps skeletal muscle compartment. This 75% loss is analogous to the VML 
injuries treated in the translational portion of the present manuscript. The defects within the 
treated group were filled with a biologic scaffold composed of ECM. Non-resorbable marker 
sutures were placed at the corners of the defect in both groups and were used to identify the 
defect margins. The time points for evaluation were 7, 14, and 56-72 days (n=4 per time point / 
group). Microscopic analysis included histochemistry and immunolabeling to examine PVSCs 
and skeletal muscle tissue. 
5.2.2 Patient Selection and Screening Examination 
A minimum of 6 months from time of injury and age between 18-70 years were inclusion criteria 
for experimental surgical intervention with the ECM scaffold approach. In addition, a minimum 
of 25% loss of muscle mass as determined by MRI or CT and a documented minimum loss of 
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25% function, compared to the contralateral muscle group, were required. Innervation to existing 
musculature within the injured compartment was considered to be necessary for a positive 
outcome and was confirmed prior to surgical procedure based upon electromyography (EMG) 
testing.  Exclusion criteria included open wounds or active infection at the site of injury, 
bleeding disorders, medical comorbidities that would impair wound healing, and inability to 
comply with physical therapy. Informed consent was obtained after the nature and possible 
consequences of the study were explained. The criteria for patient selection are summarized in 
Table 3. 
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Table 3: Patient exclusion and inclusion criteria. Patients were screened against a priori established exclusion and 
inclusion criteria. 
 
 
5.2.3 Physical Therapy Screening 
The screening evaluation included a clinical examination performed by a licensed physical 
therapist. A medical history was obtained and the subject goals for participation in the study 
were documented. The greatest perceived functional limitations were identified. Active and 
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passive ranges of motion were assessed using a goniometer, and strength of the affected region 
was assessed using a hand-held dynamometer. Functional assessments were established on a 
patient-by-patient basis and were aligned with the subject’s self-reported greatest deficits and the 
clinical examination. 
5.2.4 Pre-Surgical Physical Therapy 
Functional outcome variables were established a priori immediately following completion of the 
screening visit. Since each subject was unique in their clinical presentation, outcome variables 
that isolated tissue and functional deficits across specific joints were identified through a study 
team consensus. Outcome variables previously shown to be valid and reliable, and when possible 
aligned with the participants self-reported deficits were selected.  This custom-designed pre-
surgical rehabilitation protocol lasted 6-8 weeks, and only subjects who reached maximum 
strength and functional capacity upon completion of the pre-surgical physical therapy program, 
as determined by the treating physical therapist, proceeded to surgery. 
5.2.5 Surgical Procedure 
Procedures were performed under general anesthesia in a tertiary care medical center.  Through 
an open incision, sharp debridement of scar tissue was performed, along with selective tenolysis. 
The injured muscle compartment was reconstructed with the ECM device (MatristemTM, ACell, 
Inc. Columbia, MD). The scaffold material consisted of 8 layers of urinary bladder ECM 
laminated by vacuum pressing into a sheet configuration and measuring approximately 4 mm in 
thickness. The ECM scaffold was implanted within the VML injury site, with maximal surface 
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contact adjacent to native healthy tissue, and secured under moderate tension with either 
permanent or slowly absorbing sutures. Range of motion was then evaluated to ensure that the 
graft was secure. Care was taken to avoid contact of the scaffold with bone, and all empty space 
was obliterated prior to closure of the surgical site to ensure maximal contact of the scaffold with 
host soft tissue on all surfaces. Closed suction drains were placed in most cases prior to closure 
of the subcutis with absorbable sutures. 
5.2.6 Post-Surgical Physical Therapy 
Physical therapy that mimicked the pre-operative program was initiated within 24-48 hours post-
surgery. Pain level, range of motion, strength and functional capacity were evaluated at each 
visit. Strength measures were assessed with a hand held dynamometer. Targeted exercises were 
performed within the subject’s pain tolerance as early as the first post-operative day with the 
goal of stimulating muscle contraction and weight bearing across the scaffold implantation site. 
Subjects were instructed in a home exercise program, which they were encouraged to perform 
multiple times each day. Physical therapy visits were completed 3 times per week for the first 6 
weeks post-surgery.  The customized physical therapy program was then adjusted in frequency 
based upon the patients’ functional improvement.    
5.2.6.1 Imaging 
The MR imaging protocols included a variety of sequences in sagittal, coronal, and axial planes 
using T1-weighted spin echo, T2-weighted fast spin echo with or without fat suppression, and 
short tau inversion recovery (STIR) sequences. The CT imaging protocol included unenhanced 
axial image acquisition at a slice thickness of 1.25 mm and 2.5 mm with both soft tissue and 
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bone kernels. The kVp and mA were optimized at 120 and 240, respectively. The images were 
volumetrically reformatted into coronal and soft tissue planes.  
Imaging was reviewed by a musculoskeletal-trained radiologist. Pre-surgical MR imaging 
was assessed for: degree of loss of normal muscle bulk, muscle signal abnormality including 
presence or absence of fatty infiltration and denervation edema, integrity of the 
musculotendinous units (when possible), presence of concomitant fascial injury and 
characterization of prior post-surgical and/or post-traumatic changes. Pre-surgical CT imaging 
was assessed for similar features, with characterization of muscular attenuation replacing 
characterization of muscle signal abnormality. Characterization of the location and appearance of 
the ECM scaffold as well as a change in volume or appearance of the surrounding musculature 
was performed on the post-surgical imaging. 
5.2.7 Tissue Biopsy 
Ultrasound guided needle biopsies were taken from the scaffold implantation site on two 
separate occasions: 5-8 weeks post-surgery and again at 24-32 weeks post-surgery. The biopsies 
spanned the full length (i.e., proximal to distal) and width (i.e., medial to lateral) of the scaffold 
implantation site and ranged in number from 6-9.  The specimens were snap frozen with liquid 
nitrogen and stored at -80°C for subsequent processing.  
5.2.8 Immunolabeling Studies 
Frozen tissue sections from the rodent study were fixed in ice cold 50:50 methanol: acetone for 5 
minutes at room temperature and washed in phosphate buffered saline (PBS). To reduce non-
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specific antibody binding, tissue sections were blocked in blocking buffer (1% (w/v) bovine 
serum albumin / 2% (v/v) normal horse serum / 0.05% (v/v) Tween-20 / 0.05% (v/v) Triton X-
100 in PBS) for 1 hour. Tissue sections were then incubated in primary antibodies diluted in 
blocking buffer with mouse on mouse blocking reagent (Vector Labs, Burlingame, CA) 
according to manufacturer’s protocol at 4OC for 16 hours. The primary antibodies used for the 
immunolabeling studies were: (1) mouse monoclonal CD146 (Abcam, Cambridge, MA) at a 
1:350 dilution for identiﬁcation of perivascular cells; (2) rabbit polyclonal Neurogenin-2 (NG2, 
Millipore, Billerica, MA) at a 1:200 dilution for identification of perivascular cells and; (3) 
monoclonal anti-desmin (Abcam, Cambridge, MA) on frozen fixed tissues at 1:200 dilution for 
identiﬁcation of muscle cells. After washing in PBS, tissue sections were incubated in 
fluorophore conjugated secondary antibodies (Alexa Fluor® donkey anti-mouse 488 or 594 or 
donkey anti-rabbit 488, Invitrogen). After washing again with PBS, nuclei were counterstained 
with DAPI and slides were coated with anti-fade mounting media (Dako). 
The human tissue biopsy samples were embedded in optimal cutting temperature compound 
(OCT, Sakura Finetek, Torrance, CA) and snap frozen in liquid nitrogen. Frozen tissue sections 
(5um) were fixed in ice cold 50:50 methanol:acetone for 5 minutes at room temperature and 
washed in PBS. 
 Tissue sections were blocked in blocking buffer (1% (w/v) bovine serum albumin, 2% (v/v) 
normal horse serum, 0.05% (v/v) Tween-20 & 0.05% (v/v) Triton X-100 in PBS) for 1 hour. The 
primary antibodies were applied, diluted in blocking buffer, at 4oC for 16 hours. The primary 
antibodies used for the immunolabeling studies were: (1) 1:350 mouse monoclonal anti-CD146 
(Abcam, Cambridge, MA); (2) 1:200 rabbit polyclonal anti-Neurogenin-2 (NG2; Millipore, 
Billerica, MA); (3) 1:200 488 conjugated goat polyclonal anti-von Willebrand Factor (vWF) 
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(USBiological, Salem, MA) and; (4) 1:200 mouse monoclonal anti-desmin (Abcam, Cambridge, 
MA). After washing in PBS, the secondary antibodies were applied (Alexa Fluor® donkey anti-
mouse 488 or 594 or donkey anti-rabbit 488, Invitrogen). After washing again with PBS, nuclei 
were counterstained with DAPI and slides were coated with anti-fade mounting media (Dako).  
Tissue sections were evaluated using a Zeiss Axio-observer Z1 microscope using an x20, 0.4 
NA objective with a x1.6 Optovar magnification changer (Carl Zeiss, Thornwood, NY). A 
minimum of three fields of view from each of the surgical sites or biopsy samples were 
examined from each preclinical model (n=4) and human patient (n=5) respectively. 
 
Table 4: Quantification of Histological Findings from the Mouse Model of VML. Semi-quantitative findings of 
PVSCs and muscle cells from the preclinical portion of the study. 
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5.3 RESULTS 
5.3.1 Mouse Model of Volumetric Muscle Loss 
A murine model of VML (357) was used to evaluate the spatial and temporal presence of 
endogenous PVSCs and skeletal muscle cells during the remodeling of biologic scaffolds at the 
site of skeletal muscle injury (Table above, mouse staining semi-quant). In uninjured skeletal 
muscle, PVSCs were identified within their native peri-vascular anatomic location around von 
Willebrand Factor (vWF)+ capillaries and arterioles. PVSCs remained within their normal 
vascular-associated niche in both untreated VML defects and those implanted with an ECM 
biologic scaffold at 7 days post-injury and scaffold implantation (Figure 22A, Top). However, at 
14 days post-injury, untreated defects showed vascular-associated PVSCs while defects treated 
with ECM showed PVSCs outside their normal peri-vascular niche and in the midst of the 
degrading ECM scaffold material (Figure 22A, Bottom). At 56-72 days post-injury, the untreated 
VML defects showed scar tissue formation and no sign of new skeletal muscle formation, 
whereas defects treated with ECM showed the formation of islands of desmin+ striated skeletal 
muscle throughout the area of scaffold placement, consistent with an ECM mediated constructive 
remodeling effect (Figure 22 B).  
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Figure 32: Progenitor cells are present at the site of constructive remodeling by ECM scaffolds surgically 
placed within sites of VML injury. CD146+ PVSCs (red) remained in their normal anatomic location, surrounding 
vascular structures (von Willebrand Factor (vWF), green) at 7 days post-injury in both untreated and ECM treated 
defects in a mouse model of VML (A, top panels). After 14 days, untreated VML defects showed perivascular cells 
maintained their vascular association; conversely, ECM-treated defects were populated with CD146+ PVSCs 
outside their normal niche (arrows), suggesting that they participate in the remodeling of the ECM scaffold (A, 
bottom panels). Untreated defects from the mouse model of VML showed no signs of skeletal muscle formation, 
while ECM scaffold treated defects showed the formation of desmin+ (green) and striated skeletal muscle cells at 
56-72 days post-injury (B). ECM treatment showed desmin+ cells near the interface with underlying native muscle 
(dotted line), as well as throughout the center of the ECM graft (inset). Scale Bar = 50 μm. 
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5.3.2 Clinical Cohort Study Design 
A clinical trial examining outcomes after reconstruction of VML with ECM was conducted with 
informed patient consent and approvals from the Institutional Review Board of the University of 
Pittsburgh and DoD Human Research Protection Office [ClinicalTrials.gov Identifier: 
NCT01292876]. A schematic of the clinical cohort study design is shown in Figure 23.  Briefly, 
patients were screened against established exclusion & inclusion criteria (Table 3) and those 
enrolled were first entered into a custom-designed physical therapy program based upon their 
specific muscle deficit to optimize function. The ability to perform tasks which quantified the 
function of the injured/missing muscle tissue were tracked during the pre-surgical training period 
until a plateau was reached and no additional measurable progress could be obtained for a 
minimum of 2 weeks; i.e., maximum function was reached based upon optimal physical therapy 
(Figure 23, Blue ramp progression). Imaging studies consisting of MRI or CT scan were 
conducted in an attempt to quantify the muscle tissue volume deficit relative to the contralateral 
limb on all patients.  
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Figure 33: Schematic of clinical study design. Potential patients were pre-screened by phone before an initial 
physical screening and functional assessment. Next, all patients completed a customized pre-surgical physical 
therapy program that focused specifically upon their individual functional deficits and that was designed to 
maximize their individual potentials prior to surgical intervention (blue ramp progression). The identification and 
maximization of functional parameters prior to surgery minimizes the likelihood that any improvement following 
ECM intervention was solely the result of the physical therapy component of care. Patients then underwent the ECM 
scaffold surgical placement procedure (grey arrows) and immediately returned to their pre-surgical physical therapy 
regimen (green ramp progression). Ultrasound guided biopsies taken from the site of scaffold implantation at 5-8 
weeks showed robust mononuclear infiltration and the presence of desmin+ (green staining) muscle cells. At 16-23 
weeks post-surgery, CT showed dense tissue consistent with skeletal muscle at the surgical site (white arrow) and 3 
of 5 patients showed functional improvement. 
The surgical procedure involved excision of local scar tissue, identification of adjacent 
vascularized and innervated muscle tissue, and placement of an acellular biologic scaffold 
material composed of porcine urinary bladder ECM (MatristemTM, ACell, Inc. Columbia, MD) 
under moderate tension to restore continuity of the injured muscle compartment. Tenolysis was 
performed if tendon gliding was restricted by scar tissue.   
Range of motion, weight bearing of the affected limb, and exercises performed within the 
subject’s pain tolerance were initiated one day post-operatively for all patients. The post-
operative rehabilitation program was designed to address the same functional deficits that were 
identified upon subject inclusion into the study and mimicked the rehabilitation program that was 
administered pre-operatively (Figure 23, Green ramp progression). Ultrasound-guided biopsy 
specimens were obtained from the implant site at locations spanning the distance between the 
proximal and distal borders of interest at both 5-8 weeks post-surgery, and then again at 
approximately 6 months post-surgery (end of the monitoring period). MRI or CT imaging was 
repeated at 6 months post-surgery. 
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 Table 5: Patient information. Relevant information from each patient included in the present study. 
 
 
5.3.3 Subjects with Volumetric Muscle Loss 
Table 5 describes the characteristics of the first five consecutive subjects enrolled in the clinical 
study. All subjects were male and at least 6 months removed from the time of injury. In 
accordance with the established inclusion criterion (Table 3), all subjects exhibited a minimum 
of 25% functional and structural deficit compared to the contralateral limb. All participants had 
previously been subjected to multiple surgical procedures and extensive physical therapy, and 
thus were considered to have exhausted all available standard of care options.   
 
 
 
 125 
Table 6: Patient Biopsy Procedure and Findings. Semi-quantitative findings of PVSCs and muscle cells from the 
clinical portion of the study. 
 
 
5.3.4 Histomorphologic Findings 
At 5-8 weeks post-surgical implantation of the ECM scaffold, the histomorphologic 
characteristics were similar for all 5 patients and showed a mononuclear cell infiltrate of variable 
density interspersed among fragments of partially degraded ECM scaffold.  Neocapillaries and 
arterioles were present in all specimens (Table 5). Randomly scattered PVSCs were both 
associated with vWF+ vascular structures and independent of any vascular structures in all 
patients except for patient number 4 (Figure 24A, Left).  Islands of centrally-nucleated desmin+ 
cells that were not associated with any vascular structure were present in biopsy specimens from 
patient numbers 3 & 5 (Figure 24B, Left) but not in biopsy specimens from any of the other 
patients.  
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Figure 34: Constructive tissue remodeling by ECM scaffolds in a human clinical application. In a human 
clinical application, CD146+ PVSCs were identified both within and outside of (arrows) their normal perivascular 
association following representative muscle biopsies from ECM scaffold treated VML defects at both 5-8 and 24-32 
weeks post-scaffold implantation (A, top panels).  CD146+ cells co-expressed the Neurogenin-2 (NG2) surface 
maker antigen, identifying them as PVSCs, in human muscle biopsies (A, bottom panels). The identification of 
PVSCs outside their normal niche suggests that they may participate in the remodeling of ECM scaffolds within 
human patients, similar to the results of the preclinical study. At both 5-8 and 24-32 weeks post-ECM scaffold 
treatment, human muscle biopsies from the site of scaffold implantation showed the formation of islands of desmin+ 
muscle cells (B), similar to the results of the preclinical study. Scale Bar = 50 μm. 
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At 6 months post-surgery, all 5 patients showed similar histologic findings. PVSCs were 
again identified both associated with vWF+ vascular structures and independent of any vascular 
structures (Figure 24A, Right). Desmin+ cells with central nuclei, indicative of actively 
regenerating skeletal muscle cells, and new mature skeletal muscle cells were seen in the 
majority of biopsy samples in all patients either as individual cells or in variably sized clusters of 
cells (Figure 24B, Right). Areas of mature skeletal muscle cells were present in biopsy samples 
from patients 2, 4 and 5.  Small blood vessels were abundant within the moderately organized 
connective tissue that represented the original scaffold placement site (Table 5).  No 
recognizable scaffold material was present in any of the biopsy specimens. 
5.3.5 Pre- & Post-Surgical Imaging 
Initial pre-surgical imaging was performed, and repeated post-surgically at approximately 6 
months for each subject. Four of the five subjects were examined using a 1.5 T MRI scanner 
(Signa HDx, GE Healthcare), whereas one subject was unable to undergo MRI examination as a 
result of retained shrapnel fragments and indwelling metallic hardware. This subject was 
examined using a CT scanner (4-slice, LightSpeed, GE Healthcare). The estimated volume of 
lost muscle ranged from 58% to 90%. Characterization of the location and appearance of the 
ECM scaffold as well as a change in volume or appearance of the surrounding soft tissue was 
performed on the post-surgical imaging. When comparing pre- vs. post-scaffold implantation, 
imaging of the injured limb showed the formation of dense tissue consistent with skeletal muscle 
at the implantation site at approximately 6 months post-surgery (Figure 25). 
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Figure 35: Imaging of affected extremity pre- and post-surgical implantation. CT images of patient three before 
and 6 months after surgical placement of an ECM bioscaffold within a site of VML. After 6 months, the site of 
bioscaffold implantation showed an accumulation of dense tissue consistent with skeletal muscle (arrows). 
 
 
5.3.6 Post-Surgical Function 
At 24-28 weeks post-surgery the subjects showed an average increase of approximately 25% and 
220% in force production and functional tasks (i.e., activities of daily living), respectively 
(Figure 26). Three of the five patients showed 20% or greater improvement of strength (range 
20%-136%) of the affected limb 6 months after surgery (Figure 27). The two subjects diagnosed 
with anterior compartment syndrome that were unable to produce any measureable force 
production before the surgical manipulation, showed no improvement in strength throughout the 
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duration of the study; yet a third subject with the same diagnosis but who retained some pre-
surgical dorsiflexion strength (3.6 lbs as determined by a handheld dynamometer) showed a 33% 
improvement in strength 6 months post-surgery.  
 
 
Figure 36: ECM-mediated constructive remodeling was associated with functional improvements. Average 
values of force production (squares) and functional task (circles) measurements from all five patients at 6-8, 10-12, 
and 24-28 weeks post-scaffold implantation. Force production and function were assessed by dynamometer and 
task/exercise completion respectively and graphed as percent change from pre-surgical maximum. Average +/- 
SEM. 
 
Six months after surgery, three of five subjects showed improvement in the functional 
outcome variables (Figure 7, Supplemental Data). Both individuals receiving ECM 
transplantation into the quadriceps region showed marked improvements in functional capacity. 
Subject 3 showed a dramatic improvement (1820%) in Single Hop Test at 6 months after 
surgery. Subject 4 showed improvements in the Chair Lift Test (324%) and Max Single Leg 
Squats (417%). Of the individuals receiving ECM transplantation to the anterior compartment, 
 130 
Subject 1 did not show any functional improvement 6 months after surgery, whereas Subjects 2 
and 5 both showed an improvement in balance measures as determined by Single Leg Stance 
time with eyes closed and the Backward Reach Test (Figure 7, Supplemental Data).  
 
 
Figure 37: Force production data from each individual patient. Strength measures as assessed with a hand held 
dynamometer from each individual patient and graphed as percent change from pre-surgical maximum (A). Data 
from each individual patient (B). 
 
 131 
5.4 DISCUSSION AND CONCLUSIONS 
The work described herein shows the remodeling potential of an acellular ECM bioscaffold 
for restoration of skeletal muscle in both a preclinical rodent model and in patients with VML. 
The preclinical portion of the study was conducted in an established model of VML (357). The 
previous study validated the model, showed the excisional defect was of critical size, and 
examined the presence of myogenic cells after 56 days (1). The present study extends these 
findings by examining the role of PVSCs and the presence of skeletal muscle cells following 
injury and ECM implantation after 72 days; and correlates the findings with histomorphologic 
results from the human study. Implantation of ECM at the site of injury was associated with 
neovascularization, the mobilization and accumulation of perivascular stem cells, and 
myogenesis in both the preclinical and clinical studies. Of note, functional improvement 
surpassing that achieved by physical therapy alone was obtained in 3 of 5 patients.   
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Figure 38: Functional task data from each individual patient. Functional measures as assessed by task/exercise 
completion from each individual patient and graphed as percent change from pre-surgical maximum (A) (Average 
+/- SEM). Data from each individual patient (B). 
 
Most strategies for restoration or de novo formation of skeletal muscle tissue are cell centric 
and typically involve the delivery of exogenous cells to sites of injured or missing tissue (70-73).  
These cell-based strategies have been largely ineffective for a variety of reasons including 
immunogenicity of allogeneic cells, inefficient methods of cell delivery, and apoptosis following 
administration to the site of interest, among others (76, 85). It is now generally accepted that 
delivered cells most likely exert therapeutic effects via paracrine-mediated mechanisms (137, 
138, 140).  
The present studies utilize an acellular approach that results in the de novo formation of 
skeletal muscle. ECM implanted bioscaffolds have been shown to provide an inductive niche 
which facilitates the recruitment and differentiation of endogenous myogenic progenitor cells (5, 
7, 200). Directed mobilization of relevant endogenous cell sources obviates the need for 
exogenous cell administration and removes the associated cell harvesting procedures, regulatory 
barriers, and any potential cell related immune responses. This translational work shows that 
ECM scaffolds, when used to treat VML in a manner that entails broad surface contact with 
adjacent vascularized and innervated muscle, serve as inductive scaffolds that promote 
remodeling of muscle tissue. 
Both the rodent study and the biopsy findings from the five patients showed PVSC’s 
removed from their normal vessel-associated anatomic location, in the midst of partially 
degraded ECM scaffold material, suggesting that these cells participate in the remodeling of the 
ECM scaffold. Histologic findings show the appearance of both immature and mature desmin+ 
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skeletal muscle cells within the implantation site. The ultrasound-guided biopsies from patients 
were collected from sites of VML that had been debrided, treated with ECM, and, after 6 
months, had formed soft tissue consistent with skeletal muscle as identified by either MRI or CT.   
In 3 out of 5 subjects, the histologic and imaging findings were concomitant with functional 
improvement. PVSC’s contribute to de novo skeletal muscle formation not only during fetal 
development, but also in adult tissue in response to acute injury (35). Therefore, it is plausible 
that the PVSC’s contribute, either directly through terminal myogenic differentiation or 
indirectly through paracrine mechanisms, to the formation of skeletal muscle in the present 
studies. The contribution of alternative sources of precursor cells from the adjacent healthy 
muscle tissue, and/or resident or circulating mesenchymal stem cells, including satellite cells, 
cannot be ruled out (76).   
PVSCs were originally described following isolation from skeletal muscle tissue, are 
identified in vivo by the expression of the CD146 and NG2 surface maker antigens, and have 
been shown to be responsive both in vitro and in vivo to chemotactic cryptic peptides created as a 
result of ECM degradation (8, 11, 27, 33, 34, 186, 360). The amount of ECM scaffold 
degradation estimated by morphologic examination in the present studies is consistent with that 
determined by quantitative 14C-labelled ECM studies in other anatomic sites (23).  
Two aspects of the protocol by which the 5 patients in the present report were treated are of 
particular note. First, the patients were all well past the acute injury response phase and had been 
subjected to multiple surgical procedures that included debridement and/or tenolysis as dictated 
by standard of care.  All procedures in these patients proved less than satisfactory and resulted in 
compromised activities of daily living. It is unlikely that the improvement noted following ECM 
treatment was part of a delayed natural healing response or the result of debridement and 
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tenolysis at the time of ECM implantation. Second, all five patients completed a pre-surgical, 
customized and intense physical therapy program that focused specifically upon their individual 
functional deficits. The identification and maximization of functional parameters prior to surgery 
and the use of these optimized parameters as baseline measures for post-operative metrics 
effectively minimizes the likelihood that any improvement following ECM intervention was 
solely the result of the physical therapy component of care. Stated differently, since each patient 
underwent a documented plateau in physical capability prior to ECM implantation, it is unlikely 
that any increase in muscle mass of the treated compartment or improvement in function was due 
to hypertrophy of the native muscle. 
5.5 LIMITATIONS AND FUTURE DIRECTIONS 
The results reported herein show similarities in the cellular remodeling characteristics 
between a preclinical model and the clinical application of ECM bioscaffolds for the treatment of 
VML. However, limitations should be noted. First, the preclinical data was limited to 56-72 days 
post-surgery, and did not evaluate muscle function. However, previous preclinical studies 
designed to evaluate function have shown significant restoration following ECM scaffold 
mediated VML repair (200, 202). The preclinical portion of the present study was specifically 
designed to evaluate the role of host PVSCs after 14 days and the presence of skeletal muscle 
after 56-72 days and to correlate these findings to tissue biopsies collected from patients 
suffering from VML. Furthermore, after 56-72 days, untreated VML defects showed the 
hallmarks of default mammalian wound healing including the formation of scar tissue and the 
lack of any notable parenchymal cell presence. Conversely, ECM-treated VML defects were 
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characterized by abundant cellularity, angiogenesis, and the onset of skeletal muscle formation 
(357). Therefore, although 56-72 days represents a relevant end point for comparing control vs. 
ECM intervention, longer studies with functional outcomes in the preclinical model are 
warranted. Secondly, while the pre-clinical model provided for the inclusion of an untreated 
control group, this was not possible in the clinical study. For example, the impact of the excision 
of scar tissue and tenolysis, when performed, cannot be assessed as an independent variable. 
Furthermore, associated placebo effects (i.e., patients may have had more confidence in their 
treated leg after implantation, which may have affected functional outcomes) were unable to be 
controlled. Some biologic scaffolds are commonly used in clinical practice to promote host tissue 
ingrowth, including fibrous tissue formation. A recent study showed functional benefits 
associated with biologic scaffold induced fibrous tissue remodeling in skeletal muscle (361). 
However, the present study employed ultrasound guided tissue biopsy, which confirmed tissue 
formation at the scaffold implantation site was consistent with the presence of non-fibrous 
skeletal muscle. Nevertheless, it was not possible to characterize the relative relationship 
between the amount of de novo skeletal muscle formation and the degree of functional 
improvement. The number of subjects was limited and two of our subjects could be considered 
non-responders. However, given the chronicity of the injury and the preoperative physical 
therapy the results in 3 subjects are notable. A common finding among the non-responders was 
lack of active movement across the weakened joint. This finding should be considered in future 
studies.  
Five subjects is insufficient to conduct statistical analysis of the results, which is the reason 
the data is presented as a series of case studies. The findings described herein represent the 
interface between the preclinical and clinical application of this therapeutic approach for VML. It 
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should be recognized that in a human population with a variety of injuries and mechanisms of 
injury, each patient is unique.  No two patients will present with identical or even similar 
morphometrics, co-morbidities, or anatomic deficits.  
The clinical translation of this acellular approach for restoration of skeletal muscle in patients 
with VML is promising and the concept of providing an inductive niche that can alter the default 
scar tissue response to injury is worthy of further study.  
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6.0  DISSERTATION SYNOPSIS 
The work presented in this dissertation examined the role of source animal age upon the 
constructive tissue remodeling induced by surgically placed bioscaffolds composed of 
mammalian extracellular matrix (ECM); showed that degradation products from ECM 
bioscaffolds directly promote a constructive M2 macrophage phenotype and that ECM treated 
macrophages are chemotactic and myogenic for skeletal muscle progenitor cells; described a 
preclinical model of volumetric muscle loss (VML) and a regenerative medicine approach for 
treatment that was associated with the recruitment of perivascular stem cells; and validated the 
translational aspects of the study by showing the ability of surgically placed ECM to recruit 
progenitor cells and promote skeletal muscle formation in human patients suffering from VML. 
The major findings for each specific aim are outlined below. 
6.1 MAJOR FINDINGS 
The major findings of the present work were: 
 
Aim 1: To evaluate the host remodeling response, including macrophage phenotype induced by 
extracellular matrix (ECM) scaffolds derived from young and aged source animals. 
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• Surgically placed ECM bioscaffolds derived from younger animals were associated with a greater M2:M1 macrophage ratio and more favorable constructive tissue remodeling outcomes when compared to ECM bioscaffolds derived from older animals. 
 
Aim 2: To determine the ability of ECM to enhance the polarization of macrophages isolated 
from young and aged subjects. 
 Sub-Aim: To evaluate the effect of ECM and polarized macrophages upon the 
chemotaxis, mitogenesis, and differentiation of skeletal muscle progenitor cells. 
• Degradation products from mammalian ECM directly promote the M2 macrophage phenotype in bone marrow derived macrophages isolated from young and aged subjects. 
• ECM treated macrophages are chemotactic and myogenic for perivascular stem cells (PVSC) and skeletal muscle myoblasts. 
• Only M1 macrophages are mitogenic for skeletal muscle progenitor cells. 
• Degradation products from market weight and young source aged ECM bioscaffolds are chemotactic and myogenic for PVSCs and myoblasts. 
 
Aim 3: To determine if an ECM scaffold induced progenitor cell participation and constructive 
macrophage phenotype correlate with a constructive tissue remodeling outcome in a mouse 
model of volumetric muscle loss (VML). 
• Defects treated with a surgically placed ECM bioscaffold, after 14 days, are associated with a predominant M2 macrophage phenotype and PVSCs outside their 
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normal perivascular niche, suggesting that they participate in the scaffold remodeling. 
• These phenomena correlate with downstream site-appropriate constructive remodeling of skeletal muscle tissue in a preclinical model of VML. 
• The translational aspects of the study are validated by the ability of surgically placed ECM to recruit progenitor cells and promote skeletal muscle formation in human patients suffering from VML. 
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